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Abstract 
Metabolic syndrome, a combination of co-associated features including visceral 
obesity, dyslipidemia, hypertension, insulin resistance and increased risk of 
cardiovascular disease, has reached epidemic levels. Recent evidence has indicated a 
pathogenic role for elevated glucocorticoid (GC) levels within adipose tissue 
specifically, in obesity. Levels of the glucocorticoid regenerating enzyme 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD-1), which converts inactive GC into 
active forms within cells, are elevated in adipose tissues of obese humans. Transgenic 
overexpression of 11β-HSD1 in adipose tissue recapitulates metabolic syndrome in 
mice, including visceral obesity, perhaps because glucocorticoid receptor (GR) levels 
are higher in visceral than subcutaneous adipose tissue. Therefore, increased adipose 
GC action, especially in visceral adipose tissue, might explain the striking similarities 
between idiopathic metabolic syndrome and rare Cushing’s syndrome of plasma GC 
excess.  
One of the major contributors to obesity and metabolic syndrome is 
consumption of excessive amounts of dietary fat. Specifically, saturated fats are 
associated with obesity and insulin resistance whereas unsaturated fats are reported to 
ameliorate some aspects of metabolic disease. Interestingly, chronic high fat feeding in 
mice decreases adipose 11β-HSD1 expression, usually without changing expression in 
liver. The reduced glucocorticoid regeneration in adipose tissue may ameliorate 
metabolic disease. This study investigated the effect of diets enriched in saturated or 
unsaturated fats on adipose tissue glucocorticoid action, focusing on 11β-HSD1 and 
glucocorticoid receptor expression. 
 Two studies were carried out, one with pair-feeding (to control low-fat diet) and 
one with ab libitum feeding. In both studies, a diet high in saturated fat (stearate) 
resulted in significant weight loss whereas a diet consisting of 58% mixed fats resulted 
in significant weight gain. In the ab libitium study (but not in pair-fed animals) both 
mono-unsaturated (oleic) and poly-unsaturated (safflower) fat-enriched diets induced 
weight gain and hyperinsulinaemia and lowered levels of adipose11β-HSD1 when 
compared to control diet. These data suggest that diets high in saturated fats elevate 
adipose tissue and liver 11β-HSD1 levels which might contribute detrimentally to, or 
         
 V 
offset, any improvements in the systemic metabolic profile. Conversely, unsaturated fats 
cause an adipose-specific down-regulation of 11β-HSD1. 
In addition, genetic evidence from human and animal studies has shown that 
regulation of glucocorticoid production and receptor density may be an important factor 
determining visceral adiposity. The role of adipocyte GR levels in determining visceral 
adiposity was investigated. Two types of transgenic mice were generated with altered 
GR levels in adipocytes using the adipocyte-specific aP2 promoter; one with a “sense” 
rat GR cDNA (2 independent lines; D- and B-FSG) and one with an “anti-sense” rat 
GR-cDNA (GR-5).  Initial characterisation of D- and B-FSG mice showed expression 
of rat GR mRNA in both female and male transgenic mice with D-FSG showing a 
higher copy number than B-FSG.  In D-FSG transgenic mice, female mice of the F1 
generation had greater adipose tissue mass than non-transgenic littermates. A 6-month 
high fat study was then carried out on line D-FSG. However, no differences in body 
weight, food intake, adipose tissue weight or blood pressure were found in either males 
or females. Further investigations of the levels of rat GR mRNA expression within 
various adipose tissues showed variable transgene expression between different 
generations of B- and D-FSG lines and even between adipose tissues within the same 
mouse. In contrast, following 6-months high fat diet, female mice under-expressing GR 
within adipose tissues (GR-5) showed a significant reduction in body weight and 
subcutaneous adipose tissue weight compared to their non-transgenic littermates. These 
data suggest that adipose GR density is an important determinant of visceral adiposity, 
in a sex-specific manner. 
Collectively, the data in this thesis support a role for GR density and GC 
metabolism in adipose tissue as important determinants of adiposity in mice. Drugs that 
manipulate these targets are of therapeutic interest. 
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1 Introduction 
 Obesity occurs when energy intake into the body exceeds energy expenditure, 
resulting in undesirable weight gain. The severity of obesity is indicated by body mass 
index (BMI), with BMI of 25 and above classified as overweight and over 30 as obese 
(James, Rigby et al. 2006). Obesity, especially visceral obesity (central, android, intra-
abdominal fat), has been associated with various health complications including 
hypertension, type 2 diabetes, dyslipidemia, insulin resistance and an increased risk of 
cardiovascular disease. Together, these risk factors are collectively referred to as the 
Metabolic Syndrome (reviewed in (Reaven 2006). In the last 20 years, obesity has 
reached epidemic proportions in western countries and is increasingly prevalent in 
developing countries. In the UK, >35% of the population is currently estimated to be 
clinically obese (Rennie and Jebb 2005).  
 
1.1 Contribution of diet to obesity, metabolic syndrome and 
insulin resistance 
Imbalanced energy intake (e.g. high intake of energy dense foods rich in simple 
sugars and high in fat) and energy expenditure (e.g. lack of exercise) results in obesity, 
with fat accumulation mainly in adipose tissue. These changes usually result in reduced 
body tissue sensitivity toward insulin and the development of insulin resistance, with a 
strong association between increased adiposity and insulin resistance (Fujioka, 
Matsuzawa et al. 1987). The obesity epidemic observed in modern society has occurred 
so rapidly that environmental factors must be to blame. One recognized contributory 
factor in this process has been the widespread increase in the availability and 
consumption of highly palatable diets, high in fat, sugar and salt. Whilst there are rare 
genetic conditions that cause severe and largely uncontrollable food intake behaviour in 
humans (O’Rahilly et al., 2002), it is believed that these obesogenic foods short-circuit 
the natural satiety mechanisms found in normal people and thus contribute to the more 
common and idiopathic forms of obesity (Friedman 2000; Dallman, la Fleur et al. 2004; 
Morton, Cummings et al. 2006). Furthermore, certain types of fatty acids within the diet 
have a more profound effect, not only on normal satiety mechanisms, but also on the 
direct metabolic systems that control the physiological processes that handle and store 
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the excess nutrients in the body (Friedman 2000; Dallman, la Fleur et al. 2004; Morton, 
Cummings et al. 2006). 
 
1.1.1  Inflammation and obesity 
Increasingly, evidence is accumulating to show that in obesity, adipose tissue is 
hypoxic and “inflamed” (Hotamisligil 2006; Hotamisligil and Erbay 2008). The 
hallmarks of this chronic inflammatory state are increased macrophage content within 
adipose tissue in obesity and an increase in pro-inflammatory macrophage markers 
(Hotamisligil 2006; Hotamisligil and Erbay 2008). Adipocytes within adipose tissue act 
not only as energy stores for excess nutrients but also function as endocrine cells to 
regulate energy intake and expenditure. Adipocytes synthesize and secrete hormones as 
well as various inflammatory cytokines (adipokines) including Tumor necrosis factor-α 
(TNFα), Interleukin-6 (IL-6), leptin, monocyte chemotactic protein-1 (MCP-1) and 
plasminogen activator inhibitor type 1 (PAI-1) (reviewed in (Wellen and Hotamisligil 
2005). During obesity, increased adipocyte volume and number is associated with 
elevated release of free fatty acids, which in excess can cause lipotoxicity within tissues 
(Wei, Wang et al. 2006). This results in activation of inflammatory signaling pathways 
such as Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (see 
below) as well as increased production of the pro-inflammatory adipokines, TNFα and 
IL-6 which have been linked with insulin resistance, hyperlipidemia and hypertension 
(Jump and Clarke 1999; Wajchenberg 2000). Recent studies in mice have also shown 
that obesity alters the balance between the T helper type 1 (Th1) and the humoral Th2 
response, resulting in increased cytotoxic T cells and macrophages within adipose 
tissue, particularly in visceral fat depots (Lumeng, Maillard et al. 2009). 
1.2 Dietary lipid 
The development of metabolic syndrome is closely related to the kind of food being 
consumed. Dietary fat is an important macronutrient for growth and development and it 
functions as an important source of energy as well as playing an essential role in 
maintaining the structure of cellular membranes, as fatty acids function as 
building blocks of the phospholipid bilayer. This is important as distortion of the 
membrane structure can affect its permeability and protein content. Over the last 
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decade, a number of studies have shown that dietary fats as well as endogenous lipids 
modulate cell differentiation and metabolism by affecting gene expression (Duplus, 
Glorian et al. 2000; Dussault and Forman 2000; Madsen, Petersen et al. 2005). Fatty 
acids derived from dietary fats have an important role in cell signaling and can also 
serve as precursors for steroid and postaglandin synthesis.  
Triglyceride (TG) is the main form of lipid in the body and consists of a 
molecule of glycerol esterified with 3 fatty acids. TG is derived either from the diet or is 
synthesized endogenously; both fat and liver can synthesize and store TG. TG plays an 
important role in metabolism as an energy source and is transported within the body. 
High levels of plasma TG have been linked to increased risk of developing 
atherosclerosis, heart disease and stroke (Labreuche, Touboul et al. 2009). Plasma TG 
which is derived from dietary lipid is transported from the small intestine to the liver in 
the form of chylomicrons. In the liver it is packaged as very-low-density lipoprotein 
(VLDL) for export from the liver. In peripheral tissues, TG is released from VLDL and 
broken down by lipoprotein lipase (LPL) in a process called lipolysis; into glycerol and 
free fatty acids, which are then stored or utilized in tissues (Reshef, Olswang et al. 
2003). Other than TG, dietary fats include cholesterol which is essential for maintaining 
cellular membrane structure and permeability. Like TG, cholesterol is also synthesized 
de novo if dietary intake is not sufficient to meet demands. Cholesterol is found in 
animal fat which is also high in saturated fat. Once ingested it is packaged by the liver 
as low density lipoprotein (LDL) and released into the bloodstream for transport to 
tissues, including adipose tissue for storage, and skeletal muscle for consumption. LDL 
is generally considered to be “bad” cholesterol as numerous studies have shown that 
elevated plasma LDL levels are associated with increased risk of cardiovascular disease 
(Beaven and Tontonoz 2006). In contrast, high density lipoprotein (HDL), the so-called 
“good” cholesterol, is associated with reduced risk of cardiovascular disease (Grundy 
1998). HDL is responsible for transporting excess cholesterol from peripheral tissues to 
the liver in a process termed reverse cholesterol transport (Beaven and Tontonoz 2006). 
In liver, excess cholesterol is catabolized to bile acids (Beaven and Tontonoz 2006).  
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1.2.1 Dietary fats, saturation, chain length and bioactivity 
In general, there are two types of dietary fats; saturated and unsaturated fat. The rate of 
fat absorption is influenced by the structure of the fatty acid (Fig. 1.1) (Ramirez, Amate 
et al. 2001). Saturated fats (having no double bonds in their structure) are usually found 
within animal products and processed food (e.g. fast food) which is high in 
hydrogenated oil. Saturated fat such as stearate, which is composed of 18 carbons with 
no double bonds (C18:0), are most strongly associated with the development of insulin 
resistance. Diets high in saturated fatty acids have been shown to impair glucose 
metabolism by decreasing glucose uptake in muscle and lipid packaging and export in 
the liver (Sampath and Ntambi 2005). In contrast, unsaturated fats (having one or more 
double bonds in their structure), found commonly in plants and oily fish-derived foods, 
are associated with improved insulin sensitivity and reduced risk of metabolic disease 
(Manco, Calvani et al. 2004). Dietary unsaturated fats can be sub-divided into mono-
unsaturated (one double bond, e.g. oleic acid; C18:1) and poly-unsaturated fat (more 
than one double bond). Poly-unsaturated fats such as linoleic (n-6) and linolenic (n-3) 
acid that are found in vegetable oils are essential constituents of the human diet.  
As well as influencing cellular metabolism by contributing fatty acids and metabolites, 
some lipids can directly influence gene expression through binding themselves or 
through metabolite binding to lipid-sensitive nuclear receptors including the peroxisome 
proliferator-activated receptors (PPARs) (see below) and the oxysterol receptors, the 
liver X receptors (LXRs) (see below). PPARs and LXRs as well as the receptor for 
glucocorticoids (GR), are expressed in cells and tissues with key roles in energy 
homeostasis and inflammation (Bookout, Jeong et al. 2006; Fievet and Staels 2009), 
suggesting that they are important regulators of both metabolism and inflammation. 
 
1.2.2 Carbohydrates 
Apart from dietary fat, dietary carbohydrates are also macronutrient that are critical in 
the development of obesity. Various studies have shown that a low carbohydrate diet is 
associated with improved insulin sensitivity, lower  fasting  plasma  TG levels and 
weight  loss (Bradley,  Spence et al. 2009; Leite,  DeOgburn et al. 2009). 
In general, carbohydrates are subclassified into mono-, di- and poly-saccharide 
according to the number of sugar units present, with each having a different impact on 
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Figure 1.1 The molecular structure of saturated and mono-unsaturated fatty 
acids 
Fatty acids essentially consist of carboxylic acid with long hydrocarbon chains. There 
are two types of fatty acids; saturated and unsaturated. (A) Saturated fatty acids have all 
bonding positions between carbons filled by hydrogens with no double bonds. An 
example of saturated fat, stearic acid, is shown above. (B) Unsaturated fatty acids have 
one or more double bonds between the carbons; oleic acid, an example of a mono-
unsaturated fatty acid is shown. 
Adapted from http://science.csustan.edu/stone/2090/stearic.htm and 
http://www.tripleomegaplus.com/drho/Chapter2a.html 
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metabolism.  Under conditions of normal energy balance, dietary carbohydrates are 
absorbed in the intestine and delivered to the liver. Carbohydrates are also utilized by 
tissues as an energy source and can be temporarily stored by liver and muscle in the 
form of glycogen. However, when dietary carbohydrates become excess to energy 
requirements, the rate of de novo lipogenesis within the liver is increased, channeling 
excess glucose to fatty acids, which are subsequently combined with glycerol to form 
TG and are secreted as VLDL from the liver. 
 
1.2.3 Regulation of lipid and glucose homeostasis 
As mentioned above, dietary fats can affect gene expression and cellular 
differentiation associated with metabolism through different nuclear receptors; 
including the PPARs and LXRs as well as other transcription factors such as sterol-
regulatory element-binding protein (SREBP). The PPARs regulate fatty acid oxidation, 
adipogenesis and inflammation (Jump and Clarke 1999; Madsen, Petersen et al. 2005). 
Three isoforms have been identified; PPARα, PPARγ and PPARδ (Barish 2006). 
PPARα is expressed predominantly in liver, kidney, heart and brown adipose tissue and 
is involved in regulation of lipid and carbohydrate metabolism (Barish 2006). PPARγ is 
widely expressed but is highest in adipose tissue, skeletal muscle and macrophages 
(Barish 2006). It is required for adipogenesis as well as regulation of lipid storage in 
adipocytes (Beaven and Tontonoz 2006; Sharma and Staels 2007). PPARδ is also 
widely expressed including in skeletal muscle, heart, small intestine and vascular 
smooth muscle cells (Beaven and Tontonoz 2006). Reflecting their importance in lipid 
metabolism, PPARs are the target for various hypolipidemic drugs including fibrates, 
which target PPARα and thiazolidinediones (TZD) which target PPARγ (Hansson and 
Libby 2006). Another nuclear receptor, LXRs were also found to play an important role 
in lipid, cholesterol and carbohydrate metabolism (Steffensen and Gustafsson 2004). 
Two isoforms exist, LXRα and LXRβ, both of which are activated by oxysterols 
(Barish 2006). LXRα is found principally in liver, adipose tissue, small intestine, 
adrenal gland and macrophages whereas LXRβ is expressed ubiqutinously (Barish 
2006). Activation of LXRs promotes reverse cholesterol transport and eleminates excess 
cholesterol from the body (Fievet and Staels 2009). Mice that lack LXRα have been 
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shown to have impaired expression of proteins involved in fatty acid metabolism 
including the transcription factors SREBPs (see below) and stearoyl CoA desaturase 
(SCD-1), a key enzyme responsible for converting saturated fatty acids to mono-
unsaturated fatty acids (Juvet, Andresen et al. 2003). 
In addition to the nuclear receptors, an important role in lipogenesis and 
cholesterol homeostasis has been ascribed to SREBPs, which binds to sterol response 
elements in genes involved in cholesterol and lipid synthesis (Jump and Clarke 1999). 
Three isoforms have been identified; SREBP-1a and 1c are derived from the same gene 
by different promoter usage (Osborne 2000) and are important in promoting lipid 
synthesis by regulating genes required for lipid synthesis, while SREBP-2 regulates 
genes responsible for cholesterol homeostasis (Osborne 2000). NFκB, on the other hand 
is an important pro-inflammatory transcription factor that regulates expression of 
numerous cytokine genes (e.g. TNF-α and IL-6) and has been linked to inhibition of the 
insulin signaling pathway (Jump and Clarke 1999). NFκB is activated by many stimuli 
including activation of toll-like receptors (TLRs). TLR4 is expressed in adipose tissue 
and macrophages, as well as being activated by specific pathogen associated molecules 
such as lipopolysaccharide (LPS), it is activated by nutritional fatty acids contributing to 
the insulin resistance that occurs in response to obesity (Lee, Sohn et al. 2001; Shi, 
Kokoeva et al. 2006). 
 
1.3 Glucocorticoid Hormones 
Glucocorticoids (GC) are endogenous steroid hormones generated in the adrenal 
gland. Cortisol is the major active GC found in human and most mammals. Rodents 
produce a different active form, corticosterone. GCs have profound effects on 
physiological systems; maintaining homeostasis, energy balance and regulating the 
stress response (Datson, Morsink et al. 2008; McEwen 2008). GCs are also important 
for the development and maturation of tissues. They modulate intermediary metabolism, 
the immune system and influence behaviour (McEwen, Conrad et al. 1997; Chourbaji, 
Vogt et al. 2008; Kolber, Wieczorek et al. 2008). It is essential that GC secretion and 
action be tightly regulated in order to prevent detrimental effects. GC insufficiency 
(Addison’s disease) is characterized by weight loss, muscle weakness, hypotension, 
hypoglycemia, skin hyperpigmentation and depression. On the other hand, Cushing’s 
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Syndrome occurs after chronic exposure to high levels of circulating GCs, either due to 
excessive (unregulated) endogenous production of GC or administration of GC as 
medical treatment. The pathological characteristics of Cushing’s disease include 
redistribution of body fat (visceral obesity), dyslipidaemia, hypertension, muscle 
wasting, thin skin, insulin resistance/type 2 diabetes, salt and water retention, 
osteoporosis, anxiety and depression. 
  
1.3.1 Glucocorticoid Synthesis and Secretion 
 In humans, GCs are released from the adrenal gland in a diurnal pattern with 
peak levels in the morning and nadir levels in the evening and with an inverse pattern in 
rodents. GCs are synthesised in, and released from, the zona fasiculata / reticularis of 
the adrenal cortex, under the control of the hypothalamic-pituitary-adrenal (HPA) axis 
(Fig. 1.2). Excitation of the hypothalamus (e.g. by stress) causes the release of 
corticotrophin releasing hormone (CRH) and arginine vasopressin (AVP) from the 
hypothalamic praventicular nucleus (PVN) into the portal vein. CRH and AVP are then 
transported to the anterior pituitary gland where CRH binds to corticotrophin releasing 
hormone 1 receptors and AVP to vasopressin receptor 1, which both stimulates the 
release of adrenocorticotrophic hormone (ACTH) into the circulation as well as 
increasing the synthesis of proopiomelanocortin (POMC), the precursor polypeptide. 
ACTH then binds to melanocortin receptor type 2 in the adrenal cortex to stimulate the 
synthesis and release of GC (Cole, Blendy et al. 1995; Buckingham 2006).  
Plasma GC levels are tightly regulated by a negative feedback mechanism which 
mainly acts at the hypothalamus to inhibit CRH and AVP secretion and at the pituitary 
to suppress ACTH release and repress POMC transcription. The feedback mechanism is 
sensitive to increased levels of circulating GC and regulated by both glucocorticoid 
receptor (GR) and mineralocorticoid receptor (MR) (Reul and de Kloet 1985). GR 
predominantly regulates stress-induced cortisol secretion and the circadian peak, 
whereas MR regulates the basal circadian secretion of GC (Reul and de Kloet 1985).  
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Figure 1.2 Regulation of glucocorticoid secretion in the hypothalamus-pituitary-
adrenal (HPA) axis 
Schematic diagram showing the HPA axis and the principal loci involved in 
glucocorticoid feedback control. Arrows with the “+” indicate positive actions leading 
to the production and secretion of glucocorticoid from the adrenal cortex. The secretion 
of glucocorticoid is auto-regulated by negative feedback (indicated by “-“) which occurs 
at two levels; via suppressing the release of corticotrophin releasing hormone (CRH) 
from the hypothalamus and inhibiting adrenocorticotropic hormone (ACTH) release and 
synthesis in the anterior pituitary. 
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1.3.2 Mechanism of glucocorticoid action 
GCs act on target cells through binding to intracellular receptors. As well as GR (also 
called the “type II” glucocorticoid receptor), GCs can also bind to MR (or the “type I” 
glucocorticoid receptor) (Bamberger, Schulte et al. 1996). GR has a lower affinity than 
MR and is glucocorticoid selective, whereas MR binds glucocorticoids (cortisol and 
corticosterone) as well as the mineralocorticoid, aldosterone. However, MR has a 
restricted distribution, being expressed mainly in classical mineralocorticoid target 
tissues such as the distal renal tubule and colon, as well as specific regions of brain and 
heart. In contrast, GR are widely distributed in the body. Like PPARs and LXR, both 
GR and MR belong to the superfamily of ligand-activated nuclear receptors (De Kloet, 
Vreugdenhil et al. 1998; Buckingham 2006). GR, like all the other nuclear receptors has 
3 major domains (Fig. 1.3). The N-terminal domain contains “activating function” 
(AF)-1, required for activation of some target genes (Giguere, Hollenberg et al. 1986; 
Hollenberg, Giguere et al. 1987). A central highly conserved DNA binding domain 
contains two highly conserved zinc fingers, essential for DNA binding (Picard and 
Yamamoto 1987; Tsai, Carlstedt-Duke et al. 1988).  The third domain of GR is the C-
terminal ligand-binding domain which binds to hormonal ligands and contains a 
dimerization interface. It also contains an activation domain, AF-2, as well as sequences 
important for heat shock protein binding and silencing of the receptor (Hollenberg, 
Giguere et al. 1987; Dalman, Scherrer et al. 1991; Pratt 1993). 
 In the absence of ligand, GR is found in the cytoplasm as part of a multi-
protein complex together with various heat shock proteins (e.g. hsp90, hsp70, hsp56, 
hsp40) and immunophilins (e.g. Cyp40, FKBP52) (Hollenberg and Evans 1988; 
Webster, Green et al. 1988; Hutchison, Scherrer et al. 1993). When unliganded, the 
GR/HSP complex exchanges constantly between the nucleus and cytoplasm (Hache, 
Tse et al. 1999). The binding of glucocorticoid to GR results in a conformational change 
in the receptor; GR dissociates from the HSP multi-protein complex and the receptor 
protein becomes hyper-phosphorylated (Dalman, Sanchez et al. 1988; Hoeck and 
Groner 1990). The nuclear localization signals within the ligand-binding domain of the 
receptor are unmasked, and the GC/GR complex translocates into the nucleus where it 
binds to glucocorticoid response elements (GREs) to stimulate or repress the
         
 11 
 
Figure 1.3: Human Glucocorticoid receptor gene structure 
(A) Schematic diagram showing the structure of the human GR gene with the transactivation domain in blue, DNA binding domain in pink, 
ligand binding domain in green and the sites of key GR polymorphisms referred in the text shown by orange arrows. (B) Alternative 
splicing results in the formation of three isoforms; human GRα, GRβ and GRγ; GRγ has an extra amino acid in DNA binding domain (not 
shown for clarity), both GRα and GRβ contain the same exons 1-8 but different versions of exon 9, resulting in different C termini in the 
encoded proteins (see text for details). Both isoforms have two subtypes; GR-A and GR-B, as a result of alternative translation initiation 
(see text for detail). Adapted from (Schaaf and Cidlowski 2003) 
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transcription of target genes (Bamberger, Schulte et al. 1996; Schaaf and Cidlowski 
2002; Lu and Cidlowski 2004). 
 There are multiple GR isoforms, all derived from a single gene and generated by 
alternative mRNA splicing and alternative translation initiation (Fig. 1.3B) (Lu and 
Cidlowski 2004; Lu and Cidlowski 2006). Each of the isoforms acts differently and may 
have a different role in regulating GC action within cells. GRα is the hormone- 
responsive active form and consists of 777 amino acids in humans (Weinberger, 
Hollenberg et al. 1985). GRβ is generated by alternative splicing of exon 9 resulting in a 
truncated C-terminal domain which does not bind ligand (Schaaf and Cidlowski 2002). 
Both proteins contain the same N-terminal and DNA binding domain, but differ in the C 
terminus, with GRα containing a 50 amino acid sequence and GRβ containing a unique 
15 amino acids sequence (Schaaf and Cidlowski 2002). GRβ has been reported to act as 
a dominant negative repressor of GRα activity by forming GRα/GRβ heterodimers and 
is postulated to be increased in GC-resistant disease (Schaaf and Cidlowski 2002). 
However, although GRβ mRNA is found in humans it does not exist in rodents and its 
relevance to human disease is controversial (Oakley, Webster et al. 1997; Otto, 
Reichardt et al. 1997). GRγ is another GR splice variant which has an additional 
arginine located between exon 3 and 4 (Rivers, Levy et al. 1999). This variant has been 
reported to repress GC activation in a carcinoma cell line (Haarman, Kaspers et al. 
2004). 
 In addition, each GR splice isoform generates additional subtypes of GR protein 
via alternative translation initiation (Fig. 1.3B) (Lu and Cidlowski 2004). This results in 
the generation of GR-A (initiating at the first ATG; Met-1) and GR-B, which initates at 
the second ATG (Met-27), located 71 bp 3’ of the first start codon (Yudt and Cidlowski 
2001). Recently, more isoforms; GR-C1, C2, C3, D1, D2 and D3 have been identified 
with varying lengths at the N-terminus (Lu and Cidlowski 2006).  
 The primary determinants of GC action are GR density and ligand 
availability, the latter determined by the activity of the HPA axis (as described above) 
and the cellular activity of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes 
(described below) (Seckl, Morton et al. 2004).  
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1.3.3 Physiological effects of glucocorticoids  
 
GCs affect many physiological processes. They are well known for their anti-
inflammatory and immunosuppressive actions and are the most commonly used drugs to 
treat a range of inflammatory and autoimmune disorders including asthma and 
rheumatoid arthritis (McEwen, Conrad et al. 1997). However, their use as anti-
inflammatory agents is limited by their effects on metabolic processes (reviewed 
below). 
 
1.3.3.1 Immune response 
GCs influence both innate and adaptive immune responses (McEwen, Conrad et 
al. 1997). GCs promote neutrophilia but also cause lymphopenia and induce apoptosis 
in lymphocytes, eosinophils and basophils (McEwen, Conrad et al. 1997). Acutely, they 
exert both anti-inflammatory and pro-inflammatory effects on macrophages and they 
also alter differentiation and activation state of leukocytes, including macrophages 
(McEwen and Magarinos 1997). GCs modulate genes involved in the initial immune 
response by suppressing Th1-cellular immunity and promoting Th2-humoral immunity 
(Mittelstadt, Galon et al. 2002). GCs also reduce the expression of various pro-
inflammatory cytokines and chemoattractants (e.g. IL-1, TNFα, IL-6, IL-8, IL-3 and IL-
4) and increase the expression of anti-inflammatory cytokines (e.g. IL-10 and 
transforming growth factor-β (TGF-β)) (Franchimont 2004).  
 
1.3.3.2 Metabolism  
The metabolic actions of GCs are closely related to hepatic and peripheral insulin 
resistance, dyslipidemia, hyperglycemia and obesity. During fasting and exercise, when 
glucose and insulin levels are low, GCs increase blood glucose levels by inhibiting 
glucose uptake and utilization in peripheral tissues, by antagonizing anabolic insulin 
action and by promoting hepatic glucose production (Dallman, la Fleur et al. 2004). 
Such actions illustrate that GC play an important role in glucose homeostasis. GCs also 
stimulate insulin secretion in vivo through central nervous system (CNS) actions that 
remain incompletely understood (Dallman, Pecoraro et al. 2005)
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However, they also act directly on pancreatic β cells to inhibit insulin 
secretion, as shown in mice over-expressing GR within pancreatic β cells (Delaunay, 
Khan et al. 1997). In addition, they impact upon insulin signaling by stimulating 
accumulation of the sphingolipid ceramide in liver and adipose tissue which has 
been shown to inhibit insulin signaling by inhibiting Akt/protein kinase B (PKB) 
phosphorylation and activation (Summers and Nelson 2005), as well as reducing 
glucose transport via translocation of membrane bound glucose transporter GLUT4 
to an internal location (Horner, Munck et al. 1987; Delaunay, Khan et al. 1997). GCs 
also increase hepatic glucose production by stimulating hepatic gluconeogenesis 
through induction of transcription of phosphoenolpyruvate carboxykinase (PEPCK), 
tyrosine aminotransferase (TAT) and glucose-6-phosphatase (G-6-Pase) (Hanson 
and Reshef 1997). Mice which lack GR within hepatocytes become hypoglycemic 
during fasting and show lower expression of genes involved in gluconeogenesis 
(Opherk, Tronche et al. 2004). In addition, GCs are also associated with hepatic fat 
accumulation as demonstrated in adrenalectomised rats treated with dexamethasone 
which show increased triglyceride (TG) synthesis, reduced fatty acid oxidation and 
accumulation of lipid within liver (Cole, Wilcox et al. 1982).  
In adipose tissue, GCs affect lipid metabolism and reduce insulin sensitivity. 
Patients with Cushing’s syndrome show redistribution of body fat from peripheral to 
central depots (Walker and Andrew 2006). In addition, GCs exert different actions 
on different adipose depots. For example, in central/visceral fat depots, GCs promote 
pre-adipocyte differentiation and increase lipogenic activity and cellular hypertrophy 
(Ailhaud, Amri et al. 1991; Samra, Clark et al. 1998). In peripheral fat depots (such 
as subcutaneous fat), GCs increase lipoprotein lipase (LPL) mRNA expression and 
stimulate lipolysis by inducing hormone sensitive lipase, resulting in the breakdown 
of TG and the release of fatty acids and glycerol from adipose tissue (Slavin, Ong et 
al. 1994; Mattsson and Olsson 2007). In brown adipose tissue, GCs decrease 
thermogenesis by down-regulating uncoupling protein (UCP-1) expression (Sell, 
Deshaies et al. 2004) . Furthermore, GCs also been shown to influence the insulin 
signaling cascade within adipose tissue. Recent studies have shown GC treatment 
down-regulates insulin receptor substrates (IRS)-1 and-2 levels, blunting the insulin-
signaling pathway (Caperuto, Anhe et al. 2006; Gathercole, Bujalska et al. 2007). In 
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addition, markers of insulin signaling, such as phosphoinostitide 3 (PI3) kinase 
activity and Akt phosphorylation, were also suppressed by GC in primary rat 
adipocytes (Buren, Liu et al. 2002; Buren, Lai et al. 2008). Studies have also shown 
that GCs influence insulin signaling in a tissue-specific manner as they down-
regulate insulin signaling proteins and glucose uptake capacity in omental but not in 
subcutaneous human adipocytes (Lundgren, Buren et al. 2004). In skeletal muscle, 
GCs modulate glucose metabolism and protein degradation. These biological effects 
are usually apparent either during fasting or stress. Under these conditions, increased 
levels of GCs inhibit glucose uptake, suppress muscle protein synthesis and induce 
protein degradation, mobilizing amino acids from muscle protein to provide 
substrate for energy generation via hepatic gluconeogenesis (Wing et al 1993). These 
catabolic effects of GCs have been associated with muscle atrophy, as observed in 
patients with Cushing’s syndrome or those on steroid therapy (Schakman, Gilson et 
al. 2008). 
 
1.3.4 Developmental and other effects of glucocorticoids 
  GCs also have a fundamental role in the development and maturation of 
organs. They are essential for foetal lung maturation (Garbrecht, Klein et al. 2006) 
and mice that are homozygous for a targeted disruption of the GR gene (GRhypo) die 
soon after birth due to severe lung atelectasis (Cole, Blendy et al. 1995). GC, are 
essential for the expression of the adrenaline-synthesizing enzyme, 
phenylethanolamine-N-methyl transferase (PNMT) in the adrenal medulla 
(Michelsohn and Anderson 1992). In addition, GCs are reported to affect the 
proliferation of adrenergic cells and suppress neuronal markers in sympathoadrenal 
progenitors, shifting them towards a chromaffin cell phenotype (Finotto, Krieglstein 
et al. 1999). However, both GRhypo and GRnull mice were shown to have normal 
numbers of adrenal chromaffin cells, despite the loss of GR-mediated signaling, but 
had no expression of PMNT (Finotto, Krieglstein et al. 1999). Other than 
development, GCs also have an important role in stress response and in behaviour. 
GR is widely expressed within the brain (including in the hippocampus, amygdala, 
hypothalamus, thalamus, cerebellum and cortex) with highest expression found in 
         
 16 
amygdala and the hippocampus, both areas important for memory, learning, mood 
and behaviour (McEwen 2005). 
Under normal conditions, GC levels are tightly regulated by the HPA axis. 
Physical or emotional stress activates the HPA axis, increasing GC secretion.  In the 
short term, this is a protective mechanism as GCs suppress inflammation and 
increase the availability of energy. But in the long term, high GC levels result in 
structural remodeling in the brain (Johnson, Farb et al. 2005). Cushing’s patients 
with elevated GC levels exhibit memory deficit, anxiety and depression (Sonino, 
Fava et al. 1993). Conversely, chronic GC deficiency is associated with aggressive 
behaviour (Kim and Haller 2007). 
 
1.3.5 Glucocorticoid receptor transgenic mice 
 To elucidate the various and tissue-specific physiological roles of GR, a 
number of transgenic mouse models have been generated. The first GR transgenic 
mouse model was created by expressing antisense GR RNA under the control of a 
human neurofilament promoter (Pepin, Pothier et al. 1992). This resulted in ~50-
70% reduction in GR levels within the brain and ~40% reduction elsewhere, 
including within the liver (Pepin, Pothier et al. 1992). These mice exhibited HPA 
axis hyperactivity and developed obesity, with increased fat mass and plasma TG 
levels, despite reduced food intake (Pepin, Pothier et al. 1992; Richard, Chapdelaine 
et al. 1993). As this model exhibited different degrees of “knockdown” of GR 
between tissues and only displayed a partial reduction in GR levels within tissues 
(Pepin, Pothier et al. 1992), the actual impact of GR function could not be fully 
investigated.  Later, mice homozygous for a hypomorphic allele of GR (GRhypo) 
were created by insertion of a neomycin phosphotransferase cassette into exon 2 of 
the GR gene (Cole, Blendy et al. 1995). This resulted in 90% of the homozygous 
mice dying at birth with respiratory failure (Cole, Blendy et al. 1995). However, 
10% of the homozygous mice survived and displayed GC insensitivity, a hyperactive 
HPA axis and adrenal hypertrophy (Cole, Blendy et al. 1995; Cole, Myles et al. 
2001). The variability in phenotype was later shown to be due to incomplete 
inactivation of the GR gene (Cole, Myles et al. 2001). To ensure complete 
inactivation of GR, mice were generated by deleting exon 3 which encodes part of 
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the DNA binding domain (GR null). All of these mice died at birth due to respiratory 
failure as a result of lung atelectasis (Finotto, Krieglstein et al. 1999). Since then, 
various transgenic mouse models (summarized in Table 1.1) including conditional 
(tissue-specific) deletion of GR have been created to overcome the neonatal lethality 
of the complete inactivation of GR. 
 
1.3.6 Polymorphisms of glucocorticoid receptor 
A number of polymorphisms have been identified within the GR gene locus, 
which are associated with altered GR sensitivity, altered hypertension, body fat 
distribution, body composition and metabolic profile (van Rossum and Lamberts 
2004; Gross and Cidlowski 2008).  
The BclI polymorphism is a restriction fragment length polymorphism 
located in intron 2, in which a G to C polymorphism occurrs at nucleotide 646 
resulting in fragments of 2.3 and 3.9 kb (van Rossum, Russcher et al. 2005). The C 
allele is considered the wide-type allele as it occurs more frequently (65%) (van 
Rossum and Lamberts 2004).This polymorphism is associated with increased GC 
sensitivity (Fleury, Beaulieu et al. 2003; van Rossum, Koper et al. 2003). When 
compared to homozygous GG carriers, GC carriers have increased visceral fat and 
are hypertensive (Watt, Harrap et al. 1992; Panarelli, Holloway et al. 1998; 
Rosmond, Chagnon et al. 2000). Another polymorphism that has been associated 
with increased GC sensitivity is the N363S polymorphism (Koper, Stolk et al. 1997; 
Huizenga, Koper et al. 1998). This single nucleotide polymorphism (SNP) is located 
in codon 363 within exon 2 altering ATT to AGT (Huizenga, Koper et al. 1998), 
resulting in a replacement of asparagine with serine. This polymorphism is located in 
the N terminus of the receptor and has been linked with higher body mass index 
(BMI), tendency to lower bone mineral density and increased insulin sensitivity with 
dexamethasone (Huizenga, Koper et al. 1998; Lin, Wang et al. 2003; Roussel, Reis 
et al. 2003). However, the impact of this polymorphism is controversial as some 
studies have found no association with increased BMI or increased GC sensitivity 
(Echwald, Sorensen et al. 2001; Rosmond, Bouchard et al. 2001)  
The ER22/23EK GR polymorphism affects codons 22 and 23 within exon 2 
of GR (van Rossum, Feelders et al. 2004). This polymorphism consists of two
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Table 1.1 GR transgenic mice and their phenotype 
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Mouse GR expression Phenotype Ref 
GRM610L Knock-in Human GR 
Poi§nt mutation that  
increase sensitivity for 
GCs 
• Reduction in plasma corticosterone and ACTH 
• Reduction in adrenal size 
• Increased sensitivity to GCs 
(Zhang, Geller et 
al 2009) 
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linked, single nucleotide changes with no change in amino acid at codon 22 (GAG to 
GAA and a change from arginine (R) to lysine (K) in codon 23 (Koper, Stolk et al. 
1997; van Rossum, Koper et al. 2002).. In vitro studies have suggested that the 
ER22/23EK polymorphism alters the mRNA structure, favouring translation 
initiation at AUG-1 (Met-1) rather than AUG-2 (Met-27) (see section 1.3.2), 
suggesting that more of the less transcriptionally active GR-A isoform is made from 
individuals with this polymorphism (Russcher, van Rossum et al. 2005). This 
polymorphism is associated with reduced GCs sensitivity, along with a better 
metabolic profile with improved insulin sensitivity and lower total cholesterol levels 
(van Rossum, Koper et al. 2002; Wust, Van Rossum et al. 2004; Koeijvoets, van der 
Net et al. 2008). Within human elderly male population, the ER22/23EK 
polymorphism was associated with a lower tendency to develop dementia, increased 
insulin sensitivity, lower levels of C-reactive protein (associated with cardiovascular 
disease) and lower mortality (van Rossum, Feelders et al. 2004; van Rossum and 
Lamberts 2004). In a younger population, male ER22/23EK carriers were taller with 
more muscle mass and in female carriers, the waist:hip ratio was found to be smaller 
than in non-carriers (van Rossum and Lamberts 2004). Although most studies have 
indicated that the ER22/23EK polymorphism is associated with a better body 
composition and metabolic profile, a recent study has also linked it with a more 
aggressive multiple sclerosis disease course (van Winsen, Manenschijn et al. 2009).  
A fourth polymorphism was found within the GR gene promoter region; the 
TthIIII polymorphism (van Rossum and Lamberts 2004). It has a single nucleotide 
change from T to C at 3807bp upstream from the GR mRNA start site (van Rossum 
and Lamberts 2004).This polymorphism on its own shows no association with 
insulin sensitivity, plasma glucose levels and lipid concentration. However, when it 
coexists with the ER22/23EK polymorphism, it is associated with lower insulin and 
cholesterol levels (van Rossum, Roks et al. 2004).  
 
1.4 Systemic glucocorticoids, Cushing’s disease and the 
metabolic syndrome 
Cushing’s disease is accompanied by excess plasma GC. However, the more 
common metabolic syndrome of visceral obesity, hypertension, insulin resistance / 
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type II diabetes and dyslipidemia is not (reviewed in Seckl, Morton et al. 2004). The 
striking phenotypic similarity between the common metabolic syndrome and the 
much rarer Cushing’s disease raised speculation that dysregulation of GC action also 
occurs in metabolic syndrome (reviewed in Seckl, Morton et al. 2004). 
 
1.4.1 Peripheral glucocorticoid metabolism and 11β-HSD1 
As mentioned above, despite the phenotypic similarities between Cushings’s 
disease and metabolic syndrome, obesity is not characterized by plasma cortisol 
excess (Seckl, Morton et al. 2004). Indeed, although there is some evidence for HPA 
axis activation in obesity, plasma levels of GC may even be low due to increased GC 
clearance by the A-ring reductase pathways (Livingstone, Jones et al. 2000, 
reviewed in Seckl, Morton et al. 2004). However, it has become clear in recent years 
that idiopathic obesity is associated with an increased level of GC reamplification 
within the adipose tissue, by the intracellular enzyme 11β-dehydroxysteroid 
dehydrogenase (11β-HSD1) (reviewed in Seckl, Morton et al. 2004 and see below). 
Thus, despite normal circulating GC levels, the similarities between cushingoid and 
idiopathic obesity are hypothesized to result from increased GC action within 
adipose tissue (Seckl, Morton et al. 2004). Note that liver GC regeneration by 11β-
HSD1 is a major contributor to plasma GC levels (Paterson, Holmes et al. 2007) and 
is generally lower in obesity (Livingstone, Jones et al. 2000). 
 
1.4.2 Pre-receptor glucocorticoid metabolism 
11β-HSD catalyses the interconversion of active GC (mainly cortisol in humans and 
corticosterone in rodents) and inert 11-keto forms; cortisone in human and 11- 
dehydrocorticosterone (11-DHC) in rodents (reviewed in Seckl 2004) (Fig. 1.4). 
Two isozymes exist, 11β-HSD type 1 and type 2. Each of these enzymes has a 
distinct physiological role and tissue distribution (reviewed in Seckl, Morton et al. 
2004; Tomlinson, Walker et al. 2004). 




Figure 1.4 Interconversion of active and inactive glucocorticoids by 11β-
hydroxysteroid dehydrogenase (11β-HSD) 
In vivo, the conversion of active to inactive GC is catalyzed by 11β-HSD2; a high 
affinity (for cortisol), nicotinamide adenine dinucleotide (NAP+) - dependent 
enzyme. It is highly expressed in the kidney, sweet glands, salivary glands, colon 
and the placenta. The regeneration of active GCs is catalyzed by 11β-HSD1, which 
is an NADPH- dependent enzyme and it is widely expressed in many tissues (e.g. 
liver, adipose tissue, lung and brain) (Ricketts, Shoesmith et al. 1998; Seckl, Morton 
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1.4.2.1 11β-dehydroxysteroid dehydrogenase type 2 (11β-HSD2) 
11β-HSD2 is a high affinity, nicotinamide adenine dinucleotide (NAD)-
dependent dehydrogenase enzyme which inactivates GCs (Brown, Chapman et al. 
1996). During development, 11β-HSD2 is widely expressed in the developing fetus 
and in placenta (Diaz, Brown et al. 1998), protecting the fetus from maternal GCs 
which otherwise reduce birth weight and possibly cause lifelong hypertension, 
hyperglycemia and anxiety behaviour (Lindsay, Lindsay et al. 1996; Benediktsson, 
Calder et al. 1997; Nyirenda, Lindsay et al. 1998; Kotelevtsev, Brown et al. 1999; 
Holmes; Abrahamsen et al. 2006; Cottrell and Seckl 2009). During adulthood, 11β-
HSD2 is most abundant in mineralcorticoid-target tissues such as the kidney, sweat 
glands, salivary glands, colon and placenta (Hammer and Stewart 2006). In 
mineralocorticoid target tissues, 11β-HSD2 prevents GC occupation of MR which 
otherwise would bind GCs with high affinity (Stewart, Corrie et al. 1988; Funder, 
Pearce et al. 1990). This confers aldosterone specificity upon MR where 11β-HSD2 
is co-expressed with MR (Stewart, Corrie et al. 1988; Funder, Pearce et al. 1990). 
MR only acts as a glucocorticoid receptor in tissues where it is not co-expressed with 
11β-HSD2 – mainly the hippocampal formation of brain and the heart (Reul, Gesing 
et al. 2000; Kellendonk, Gass et al. 2002) 
 
1.4.2.2 11β-dehydroxysteroid dehydrogenase type 1 (11β-HSD1) 
11β-HSD1 is a 34 kDa glycoprotein found within the lumen of the endoplasmic 
reticulum (ER) and is anchored to the membrane by its N-terminus (Agarwal, 
Rogerson et al. 1995). This enzyme has a lower affinity for cortisol and 
corticosterone than 11β-HSD2 and is an NADPH-dependent reductase within intact 
cells, generating active GC.  It is highly expressed in liver (Agarwal, Monder et al. 
1989), brain (Moisan, Seckl et al. 1990), lung (Hundertmark, Ragosch et al. 1993), 
adipose tissue (Napolitano, Voice et al. 1998), and skeletal muscle and vascular 
smooth muscle (Walker, Yau et al. 1991; Monder 1993). 11β-HSD1 has also been 
found to be expressed in immune cells. It is induced upon macrophage 
         
 28 
differentiation from monocytes (Thieringer, Le Grand et al. 2001) and is induced in 
macrophage cell lines following activation by LPS (Thieringer, Le Grand et al. 
2001). In a number of cell types, 11β-HSD1 expression is increased by pro-
inflammatory cytokines such as TNFα and IL-1 (reviewed in Chapman, Coutinho et 
al. 2009). Recently it has been proposed that 11β-HSD1 modulates inflammatory 
processes in rheumatoid arthritis and atherosclerosis (Hermanowski-Vosatka, 
Balkovec et al. 2005; Schmidt, Weidler et al. 2005; Hardy, Filer et al. 2006; Hardy, 
Rabbitt et al. 2008). Administration of a selective 11β-HSD1 inhibitor to 
Apolipoprotein E deficient (Apoe-/-) mice slowed the formation of atherosclerotic 
lesions (Hermanowski-Vosatka, Balkovec et al. 2005) although more recent studies 
have not replicated this finding (Lloyd, Helmering et al. 2009). Data from human 
studies as well as various rodent models have highlighted the importance of this 
enzyme in the pathogenesis of metabolic syndrome and obesity. Many studies have 
shown that obese humans have increased 11β- HSD1 in their adipose tissue, with a 
strong association between BMI and adipose 11β-HSD1 expression (reviewed in 
Wake, Rask et al. 2003, Seckl et al 2004, Stewart 2005). Some rodent models of 
obesity (e.g. Zucker rats, leptin deficient ob/ob mice) also have increased levels of 
11β-HSD1 in adipose tissue (Livingstone, Jones et al. 2000). However, an inverse 
correlation between BMI and 11β-HSD1 activity in primary omental human pre-
adipocytes has been shown (Bujalska, Gathercole et al. 2008). Mice which are 11β-
HSD1-deficient (11β-HSD1-/-) mice are viable, fertile and have a normal lifespan 
(Kotelevtsev, Holmes et al. 1997). Importantly, they are protected from the adverse 
metabolic effects of high fat diet and have improved glucose tolerance and insulin 
sensitivity (Kotelevtsev, Holmes et al. 1997; Morton, Holmes et al. 2001; Morton, 
Paterson et al. 2004). Mice with liver-specific overexpression of 11β-HSD1 (using 
the Apoe enhancer-promoter) were found to be mildly insulin-resistant, dyslipidemic 
and hypertensive, without obesity (Paterson, Morton et al. 2004). However, 
overexpression of 11β-HSD1 specifically in adipose tissue of transgenic mice (using 
the aP2 enhancer-promoter) caused visceral obesity, hyperinsulinemia, hypertension
         
 29 
and insulin resistance and has provided a mouse model of the metabolic syndrome 
(Masuzaki, Paterson et al. 2001; Masuzaki, Yamamoto et al. 2003). Interestingly, in 
both rats and mice, high fat diet (both short term and up to 18 weeks), reduced 11β-
HSD1 expression specifically within adipose tissue (Morton, Ramage et al. 2004; 
Drake, Livingstone et al. 2005). It has been proposed that this down-regulation of 
11β-HSD1 within adipose tissue is an important mechanism to combat obesity 
(Morton, Ramage et al. 2004). 
 
1.5 Aim of the thesis 
Obesity, particularly abdominal (visceral) obesity, is associated with 
increased risk of hypertension, insulin resistance and diabetes mellitus, 
hyperlipidaemia, and cardiovascular disease (the metabolic syndrome). Both human 
and animal studies have shown that regulation of GC production and or receptor 
density may be an important factor in determining visceral adiposity. 
 
1.5.1 Hypothesis  
GC action (GR density and 11β-HSD1-determined ligand availability) within 
adipose tissue is an important determinant of adipose tissue distribution and mass. 
 
1.5.2 Aims of the thesis: 
To test this hypothesis, 2 approaches were undertaken: 
1. To investigate the effects of dietary fat upon adipose parameters of GC 
action, the effect of different types of dietary fat upon expression of 11β-
HSD1 and GR in adipose tissues and liver of mice were examined. 
2. To test whether GR density in adipose tissue is an important determinant 
of fat mass and distribution, a transgenic model designed to have increased 
GR levels specifically within adipose tissue was created and the effect of 
chronic high fat diet upon adipose GC action was investigated in these mice.   
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2  Materials and Methods 
2.1 Materials 
Chemicals and molecular biology reagents 
 
All chemicals were purchased from Sigma-Aldrich Company Ltd or BDH Merck Ltd 
unless stated otherwise (supplier addresses can be found in Appendix A). Other 
materials were obtained as stated below: 
 
1kb DNA ladder    Invitrogen Life Technologies  
20 x SSC     Invitrogen Life Technologies  
Anti-rabbit SPA reagent   PerkinElmer LAS (UK) Ltd 
Bacto yeast extract    Becton, Dickinson and company 
Bacto tryptone     Becton, Dickinson and company 
Blotting grade blocker non fat dry milk         Bio-Rad Laboratories Ltd 
Caesium chloride    Invitrogen Life Technologies  
Calf intestinal phosphatase   Invitrogen Life Technilogies 
Deoxynucleotide triphosphates (dNTPs) Promega Corporation  
DNeasy tissue kit    Qiagen Ltd    
Ethanol     Hayman Ltd  
ECLTM western blotting detection reagent Amersham Pharmacia Biotech UK Ltd 
Glucose hexokinase reagent   Thermo fisher scientific Inc 
Glucose     Thermo fisher scientific Inc 
High DNA mass™ ladder   Invitrogen Life Technologies  
Hybond N+ nylon membrane   Amersham Pharmacia Biotech UK Ltd  
DNA Polymerase I (Klenow) Fragment Promega Corporation 
Low melting point agarose   Invitrogen Life Technologies 
LightCycler® 480 probes master  Roche Diagnostic Ltd 
NICK columns    Amersham Pharmacia Biotech UK Ltd  
Nitrocellulose/filiter paper sandwich             Invitrogen Life Technologies  
NuPAGE® antioxidant   Invitrogen Life Technologies  
NuPAGE® LDS sample buffer (4x)  Invitrogen Life Technologies  
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NuPAGE® MOPS SDS running buffer Invitrogen Life Technologies  
NuPAGE® Novex 4-12% bis-Tris Gel  Invitrogen Life Technologies  
NuPAGE® sample reducing agent (10x) Invitrogen Life Technologies  
NuPAGE® transfer buffer   Invitrogen Life Technologies  
Phenol      Fisher Scientific UK Ltd 
Protein assay reagent A    Bio-Rad Laboratories Ltd 
Protein assay reagent B    Bio-Rad Laboratories Ltd 
Protein standard II     Bio-Rad Laboratories Ltd 
QIAEXII gel extraction kit   Qiagen Ltd 
Reverse transcription system                          Promega Corporation  
Rediprime II random primer labeling kit Amersham Pharmacia Biotech UK Ltd  
Riboprobe in vitro transcription system  Promega Corporation  
RNAse Zap     Applied Biosystems 
RNAsin® ribonuclease inhibitor  Promega Corporation  
RNA wash concentrate   Anachem Ltd 
RNAID matrix    Anachem Ltd 
RPA IIITM kit     Applied Biosystems 
Seakem LE agarose    Cambrex Corporation 
SeeBlue® Plus2 pre-stained standard  Invitrogen Life Technologies  
TaqMan® Gene expression assay                  Applied Biosystems  
Taqbead™ hot start polymerase  Promega Corporation  
Triglyceride     Thermo fisher scientific Inc 
Triglyceride liquid stable reagent  Thermo fisher scientific Inc 
TRIzol®     Invitrogen Life Technologies  
Tween 20     Bio-Rad Laboratories Ltd 
NICK columns    Amersham Pharmacia Biotech UK Ltd  
[α32P]-dCTP (3000 Ci/mmol, 10mCi/ml) PerkinElmer LAS (UK) Ltd 
[3H]-corticosterone     PerkinElmer LAS (UK) Ltd 
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2.1.1 Solution and buffers 
1kb ladder 30µl 1kb ladder, 60µl glycerol, 120µl H2O, 5µl 
loading dye 
2 x HBS (500ml) 8g NaCl, 0.2g Na2HPO4, 6.5g HEPES, pH7.0 
5M potassium acetate (500ml) 127.21g potassium acetate, 57.5ml glacial acetic 
acid 
10 x MOPS (1 litre) 83.7g MOPS, 8.2g Sodium acetate, 3.72g EDTA, 
pH 7.0 
10 x TAE (1 litre) 242g Tris base, 57.1ml glacial acetic acid, 0.5M 
EDTA, pH8.0 
10 x TBE (1 litre) 108g Tris base, 55g boric acid, 40ml 0.5M EDTA 
10 x TBS (1 litre) 24.4g Tris base, 80g Nal, 38ml HCl 
20 x SSC (500ml) 87.7g NaCl, 44.1g citric acid, pH 7.0 
Alkaline SDS solution 0.2M NaOH, 1% SDS 
Borate buffer 0.133 M boric acid, 67.5mM NaOH +HCl, pH 7.4 
containing 0.5% bovine serum albumin (BSA), 1% 
methanol and 0.1% ethylene glycol 
Depc treated H2O 5 drops diethyl pyrocarbonate (depc) added to 
500ml H2O; left to stand 1h then autoclaved 
GTE (500ml) 50mM glucose, 10mM EDTA, 25mM Tris, pH8.0 
TE buffer (500ml) 10mM Tris, 1mM EDTA, pH8.0 
Transfection assay buffer 
(50ml) 
0.359g Tricine, 0.514g dithiothreitol (DTT), 20µl 
0.5M EDTA, 2.43g MgCO3, 267µl 1M MgSO4, 
10mg coenzyme A, pH7.5 
Transfection lysis buffer 
(50ml) 
25mM Tris phosphate (pH8.0), 2mM DTT, 1% 
Triton X 100, 10% glycerol 
LB (1 litre) 
Luria Broth (LB) 
10g tryptone, 5g yeast extract, 5g NaCl, autoclaved 
immediately 
LB/Amp agar plates (1 litre) 10g tryptone, 5g yeast extract, 5g NaCl, 10g agar, 
solution was autoclaved, and 100mg/ml ampicillin 
added once agar had cooled to ~45ºC, then plates 
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poured immediately  
Loading dye 2g Ficoll 400, 100mg SDS, 2.5mg bromophenol 
blue, 25mg xylene cyanol, 10ml 0.1M EDTA 
(pH8.0) 
Phosphate Buffer (500ml) 13.1g Sodium phosphate monohydrate, 42.6g 
anhydrous Na2HPO4, 0.93g EDTA 
Phosphate Buffered Saline  
(1 litre) 
8.00g NaCl, 0.2g KCl, 1.44g Sodium phosphate 
monohydrate, 0.24g Potassium dihydrogen 
phosphate, pH 7.4 
Protein extraction buffer    
(1 litre) 
50mM HEPES, 8g NaCl, 0.2g MgCl2, 0.15g CaCl2, 
0.42g NaF, 0.37g EDTA, 2.29g Sodium 
pyrophosphate 
Special depc. water 10µl 100mM DTT, 1µl RNasin, 89ul of depc 
treated H2O 
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2.1.2 PCR Primers used for genotyping and detection of 
transgene expression 
 
aP2-GR  (expected PCR product size 376bp) 
Forward  5’-GCTGCTGCACATTGCTTGTGG-3’ 
Reverse  5’-GGAGCCTTTCGAGAAATCAAGG -3’ 
 
β-Globin  (expected PCR product size 494bp) 
Forward  5’-CCAATCTGCTCACACAGGATAGAGAGGGCAGG-3’ 
Reverse  5’-CCTTGAGGCTGTCCAAGTGATTCAGGCCATCG-3’ 
 
PstI digest (expected PCR product size 100bp) 
Forward  5’-CAGGAGTCTCACAAGACACTTC-3’ 
Reverse  5’-TCACCTCCAGCAGTGACACC-3’ 
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2.1.3 Antibodies and neutralizing peptide used for Western 
blotting 
 
Anti-GR rabbit polycolonal antibody (PAI-512) Cambridge BioScience Ltd 
Anti-GR rabbit polycolonal antibody (M-20)  Santa Cruz Biotechnology, Inc. 
PA1-512 Neutralizing peptide    Cambridge BioScience Ltd  
Anti-β-tubulin monoclonal antibody   Sigma-Aldrich Company Ltd 
Goat anti-mouse IgG-HRP (Sc-2005)  Santa Cruz Biotechnology, Inc. 











All experiments were approved by The University of Edinburgh ethical 
committee and were carried out according to the UK Animals (Scientific Procedures) 
Act 1986. All experimental mice were housed in standard conditions on a 12h-light 
and 12h-dark cycle. The dietary experiments (Chapter 3) used adult (6-8 weeks) 
C57BL/6J male mice (n=12/group) given one of the following diets (all from 
Research Diets, Inc. New Brunswick, NJ); control low fat with sucrose (Research 
Diets D12329), control low fat with cornstarch (D12328), or high fat diets; oleic 
acid-enriched (D04070902), safflower oil-enriched (D04070903), stearate-enriched 
(D04070901), 58% high fat (D12331) and 45% high fat (D12451), for 1 week 
acclimatization followed by 4 weeks with body weight and food intake 
measurement. Towards the end of the experiment, mice were separated into two 
groups and killed by cervical dislocation at 0800h (n=6) or 2000h (n=6).  Blood was 
taken for measurement of plasma: corticosterone, insulin and glucose level. Liver, 
kidney, adrenal and various fat depots, gonadal (Gon), subcutaneous (Sc), 
mesenteric (Mes), retroperitoneal (RP) and brown adipose tissue (BAT) were 
collected, snap frozen on dry ice and weighed. RNA was extracted from fat depots as 
described in section 2.2.7; mRNA expression of both GR and 11β-HSD1 was 
measured by northern blotting (section 2.28). In addition, 11β-HSD1 activity was 
also measured by Lynne Ramage.   
 To test the effect of diet on transgenic mice (Chapter 4), 5 transgenic F1 
males were mated to C57BL/6J females to generate F2 offspring. Offspring were 
weaned on to either 58% high fat diet (Research Diets D12331) or 11% low fat diet 
(D12328). Ear notches were taken at weaning for genotyping (section 2.11). Both 
male and female mice (n≥12/group) were separated into different cages according to 
their genotype. Body weight and food intake were measured throughout the 6 month 
study period. At week 15 of the study, 6 mice from each group were selected for 
blood pressure measurements which were carried out weekly for 10 weeks. Glucose 
tolerance tests were carried out at week 20 of the study.  Mice (n=6/group) were 
fasted for 6h then blood was taken for plasma glucose assay (session 2.2.4). Initially, 
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10µl blood was taken from a tail nick, into EDTA-coated microtubes. Mice were 
then injected intraperitoneally (i.p.) with 2mg glucose/g body weight. Further blood 
samples (10µl/sample) were taken at 15min, 30min, 60min and 120min after the 
injection. Blood was cntrifuged at 2000rpm for 10 min at 4°C, plasma extracted and 
kept at -80°C for later analysis. Insulin tolerance tests were carried out at week 24 of 
the study. Mice (n=6/group) were fasted for 6h then blood was taken for plasma 
insulin assay. Initially, 10µl blood was taken via a tail nip then a dose of 2mU/gram 
of body weight was injected i.p.: Further 10µl blood samples were taken at 15min, 
30min, and 60min. Plasma was extracted from the blood as described above.  At the 
end of the study, mice were culled by cervical dislocation between 0730h and 0900h.  
Blood was taken for measurement of plasma corticosterone levels (section 2.2.3) in 
plasma extracted as described above. Liver, kidney, adrenal, tail and various fat 
depots; gonadal (Gon), subcutaneous (Sc), mesenteric (Mes), retroperitoneal (RP) 
and brown adipose tissue (BAT) were collected, snap frozen on dry ice and weighed.  
 
2.2.2 Measurement of plasma insulin levels 
Plasma insulin levels were measured using ultra-sensitive rat insulin ELISA 
kits (Crystalchem, Downers Grove, IL, USA), according to the manufacturer’s 
instructions. A series of insulin standards ranging from 0-5000µg/µl was used to 
produce a standard curve. A 96 well plate was coated with mouse anti-insulin 
monoclonal antibody, which bound to insulin within the samples or standard. Guinea 
pig anti-insulin antibody was then applied to the wells to “sandwich” insulin. 
Unbound material was removed by washing and horseradish peroxidase (HRP)-
conjugated anti-guinea pig antibody was added then the wells were washed again to 
remove the excess antibody. O-phenylenediamine substrate solution was then added 
to the wells (which changes color if HRP-conjugated complexes are present). The 
colour change was measured at 492nm using a plate-reader spectrophotometer 
(Molecular Devices, OPTImax) and the insulin concentration within the samples 
determined from the standard curve. 
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2.2.3 Measurement of plasma corticosterone (B) levels 
Radioimmunoassay was used to determine the total plasma B concentration 
as described (Harris, Kotelevtsev et al. 2001). Plasma was diluted 1:10 in borate 
buffer and heated at 75ºC for 30min to denature corticosterone binding globulin in 
the samples. A series of B standards ranging from 0-320nM was used to produce a 
standard curve. In a 96 well plate, 20µl of standards or samples were incubated in 
duplicate with 25µl of B antibody mixture (1 in 10,000 dilution antibody raised in 
rabbit, PerkinElmer) and 25 µl of [3H]-B in borate buffer (specific activity 
80Ci/mmol; final concentration 1.5nM) to give a total volume of 70µl. The plate was 
then covered with parafilm and incubated at room temperature for 1h. 50µl of anti-
rabbit scintillation proximity assay (SPA) beads was added to each of the samples 
and the plate re-sealed with sealant film and incubated for 10h. During the 
incubation the antibody binds to both unlabelled B and [3H]-B. Antibody bound by 
both [3H]-B and SPA beads emit a signal detected by the LKB Wallac Microbeta 
counter. The B concentration in the samples was then determined from the standard 
curve using multicalc software assay zap version 3.1. Intra and inter assay variation 
were 9.4 and 9.2% respectively. Compared with corticosterone (100%), cross 
reactivities for progesterone, deoxycorticosteron and cortisol are 7.7, 6.5 and 5.3% 
respectively. 
 
2.2.4 Measurement of plasma glucose levels 
A series of glucose standards ranging from 0-400mg/dL was used to produce 
a standard curve. In a 96 well plate, 2µl of standards or sample plasma were mixed 
with 250µl of glucose hexokinase reagent and incubated at 37°C for 3min. The 
reagent causes the glucose within the sample to be phosphorylated and NADH is 
generated. The absorbance of NADH within the plate was then measured at 340nm 
using a plate-reader spectrophotometer (Molecular Devices, OPTImax). The glucose 
concentration within the samples was determined from the standard curve. 
 
2.2.5 Measurement of plasma Free Fatty acid (NEFA) levels 
An enzymatic colour assay was used to determine free fatty acid (NEFA) 
levels in plasma. A standard curve was produced from a series of non-esterified fatty 
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acid (NEFA) standards (Thermo), ranging from 0-2.0mEq/L. In a 96 well plate, 4µl 
of standard or samples were mixed with 80µl of reagent A from Wako NEFA C test 
(Thermo) and incubated at 37°C for 10 min. Then 160µl of reagent B was added and 
the plate was incubated for a further 10min at 37°C, followed by 5min incubation at 
room temperature. The plate was then read at 550nm in the spectrophotometer 
(Molecular Devices, OPTImax). Plasma NEFA concentration was then determined 
from the standard curve.  
 
2.2.6 Measurement of liver triglyceride levels 
Frozen liver samples were homogenized in 10 vol (w/v) of isopropanol, 
shaken at room temperature for 45min, and then centrifuged at 3000rpm for 10min. 
The supernatant was removed and kept at 4°C. An enzymatic colour assay was used 
to determine triglyceride levels within samples. A standard curve was created from a 
series of triglyceride standards (Thermo), ranging from 0-2.5mmol/l.  In a 96 well 
plate, 15µl of standard or samples were incubated in duplicate with 200µl of infinity 
triglyceride liquid stable reagent (Thermo) at 37°C for 5min. The samples were then 
read at 500nm in the plate reader spectrophotometer (Molecular Devices, OPTImax). 
The triglyceride concentration was then determined from the standard curve.   
 
2.2.7 RNA extraction 
Prior to RNA extraction, in order to protect RNA samples from RNase 
contamination, all the apparatus used was autoclaved and all solutions prepared with 
depc H2O.  For RNA extraction, TRIzol reagent (Invitrogen, Paisley, UK) was used. 
Frozen tissue samples were weighed and ~50mg homogenized in 800µl of TRIzol. 
The homogenate was either used immediately or frozen at -80ºC for later extraction. 
200µl of chloroform was added to the homogenate then centrifuged at 12,000g for 
1min to remove any debris. The supernatant was then vortexed for 15s and 
centrifuged at 12,000g for 15min at 4ºC. The upper (aqueous) layer was removed, 
mixed with 30µl of RNAID matrix (Anachem, Luton, Bed, UK) and agitated for 
5min before centrifuging in a microfuge at maximum speed for 1min. The 
supernatant was removed and 500µl of RNA wash (Anachem) was added to the 
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pellet to dislodge it. This was then followed by centrifugation at 14,000g for 1 min. 
The washing step was repeated 3 times to ensure the pellet was clean. The pellet was 
resuspended in 20µl of “special depc. water” and incubated at 55ºC for 6min with a 
quick vortex before a further 6min of incubation. Finally, samples were centrifuged 
at 14,000g for 2.5min at 4ºC and 20µl of the supernatant aliquoted into 3 separate 
tubes, snap frozen on dry ice and stored at -80ºC for future use. RNA was quantified 
using a GeneQuant spectrophotometer.  
 
2.2.7.1 Assessment of RNA concentration 
 The integrity of the extracted RNA was verified by RNA gel electrophoresis. 
For each sample, 3µg RNA were mixed with 2.5µl 10x MOPS buffer, 2.5µl 
formaldehyde and 10µl deionised formamide. The mixture was incubated at 65°C for 
15min to denature the RNA then rapidly placed on ice. 2µl depc treated loading 
buffer was added to each sample. The samples were then loaded on a denaturing 1% 
agarose 1xMOPs/18% formaldehyde gel. The agarose was first melted in H2O in a 
microwave, cooled slightly then MOPS and formaldehyde were added and the 
volume adjusted to the required amount with H2O. The gel was allowed to set, then 
placed into an electrophoresis than filled with 1x MOPs buffer. Samples were then 
loaded onto the gel and run at 80V for ~3-4h bromophenol blue dye reached ~2/3 of 
the length of the gel. The integrity of the RNA was then visualized under UV light at 
260nm. 
 
2.2.8 Northern Analysis of RNA 
Prior to northern blotting, all equipment was treated with RNaseZap in order 
to prevent RNase contamination. RNA was electrophorised on denaturing 1% 
agarose gels as described above (section 2.2.7). An overnight capillary transfer was 
then set up as shown in Fig 2.1. to transfer denatured RNA from the gel to a nylon 
membrane for hybridisation, using 20xSSC as the transfer buffer. Following transfer 
the membrane was rinsed in 2xSSC and left to dry on Whatman No.3 filter paper for 
2h. The RNA was then fixed onto the membrane by UV-crosslinking (Spectronics 
Corporation, power at 1200 x 100µw/cm2). 






Figure 2.1 Schematic diagram of the northern blot transfer setup 
Schematic diagram showing the transfer step of Northern blot. After gel 
electrophoresis, RNA was transferred by capillary transfer to a nylon membrane 
(Hybond N). A “bridge” (long piece of Whatman No.3 filter paper) was soaked in 
20x SSC and was placed on top of the RNAse free gel tray.  The ends of the filter 
paper were immersed in 20x SSC, which was used as the transfer buffer.  The gel 
containing the denatured RNA was inverted and placed on top of the “bridge”. The 
nylon membrane was then placed onto the gel being careful to remove any bubbles 
trapped between the nylon membrane and the gel, followed by 3 pieces of Whatman 
No.3 filter paper.  To ensure the capillary transfer would occur, layers of dry paper 
towels were placed on the top. In addition, a glass plate was placed on top with extra 
weight above it to maintain a flat and even transfer. The whole setup was then left 
overnight at room temperature to ensure the majority of the RNA would transfer 
from the gel to the nylon membrane. 
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2.2.8.1 Hybridization 
Membranes were prehybridised at 65ºC with 18ml of phosphate buffer and 9ml of 
20% SDS in a hybridization bottle. 1ml of sonicated salmon testes DNA (10mg/ml) 
was denatured at 100ºC for 10min and added to the hybridization bottle. 
Prehybridisation was carried out at 65ºC for 3h. A radiolabelled cDNA probe was 
made for the gene of interest using a rediprimeII random-prime labeling kit. 25ng 
DNA template was diluted to 45µl with TE buffer. The probe was then denatured at 
100ºC for 15min and immediately cooled on ice for a further 10min. Denatured 
DNA was then added to the reaction tube together with 5µl of [32αP]-dCTP. The 
reaction was incubated at room temperature for 2h then labeled cDNA was purified 
through a Nick column. Briefly, columns were washed with 3ml TE buffer before 
use, then the labeling reaction was applied to the column and allowed to run in. Two 
aliquots of 400µl TE were then applied to the column. The first eluate was discarded 
and the second eluate, containing the purified probe, was collected. 1µl of the 
purified probe was added to 1ml of scintillant and counted. Generally, probes 
obtained 100,000 cpm/µl. Before adding the entire probe to the hybridisation bottle, 
it was denatured at 100ºC for 10min. The hybridization mixture was then left 
overnight at 55ºC. 
 The hybridization mixture was then disposed of and the membrane was 
washed to remove any non-specifically bound probe. Three 50ml washes were 
preformed; an initial wash at room temperature for 15min with 2xSSC, 0.1%SDS 
then followed by 2 washes, each for 15min at 65ºC, with 1xSSC, 0.1%SDS then 
0.5xSSC, 0.1%SDS. The washed membrane was then wrapped in Saranwrap and 
exposed to a phosphorimager screen (Fuji imaging plate) for 10min then read using a 
Fuji BAS phosphorimager. mRNA levels were quantitated using Aida software 
(Advance image data analyzer Version 3.44.035 Raytect, Shaffield). 
 
 
2.2.9 Ribonuclease Protection Assay (RPA) 
RPA is a method to detect and quantify RNA using a radioactive probe. 
Single stranded RNA is digested by RNase, whereas double stranded RNA (probe 
hybridized to target mRNA) is protect from RNase digestion.  
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2.2.9.1 Probe preparation 
32P-labelled cRNA probes were synthesized in vitro in 20µl reactions 
containing 4µl 5x transcription buffer, 0.4mM DTT, 2µM each ATP, CTP, UTP, 2µl 
0.1mM GTP, 20U RNasin, 1µg DNA Template, 1µl Sp6 polymerase, 3µl [32αP]-
GTP. Reactions were incubated at 40°C for 120min.  1U RQ1 RNase free DNase 
(Promega) was added to stop the reaction by incubating at 37°C for 20min. Labeled 
probe was purified using Nick Columns. Usually 100,000 cpm was obtained from 
each purified probe. 
 
2.2.9.2 Hybridisation and RNase Digestion 
Each RNA sample (8µg, unless stated otherwise) was mixed with 0.1vol 5M 
ammonium acetate, 2.5vol ethanol and 100,000cpm of each labeled probe. Samples 
were placed at -20°C for 1h for RNA precipitation to occur then centrifuged at 
12,000g for 15min to recover the pellet. The supernatant was removed and 10µl of 
hybridisation buffer III (provided in the RPAIII kit) was added to resuspend the 
pellet. Samples were then denatured at 95°C for 3min and hybridized at 42°C for 
16h.  
RNase digestions were carried out either with RNase T1 alone (cleaves at G 
residues; reduced specificity to detect mouse and rat GR mRNA) or with RNase 
A/T1 mix (cleaves at G, T and C residues to give higher specificity for exact 
sequence match to probe). RNase (either T1 or A/T1) was diluted with RNase 
Digestion Buffer III (provided in the RPAIII kit). 150µl of the diluted RNase was 
then added to each sample and incubated at 37°C for 30min. RNase digestion was 
stoppped by adding 200µl inactivation III buffer (provided in the RPAIII kit), 75µl 
ethanol and 5µg of yeast tRNA. The samples were placed at -20°C for 1h to 
precipitate RNA then centrifuged at 13,000rpm for 15min. The supernatant was 
removed and the pellet air dried for ~1 min before being resuspended in 7.5µl of gel 
loading buffer III (provided in the RPAIII kit). Samples were heated at 95°C for 
3min then placed on ice before loading onto a denaturing polyacrylamide gel.  
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2.2.9.3 Denaturing polyacrylamide gel eletrophoresis 
 Prior to making the gel, glass plates, gel spacers and comb were cleaned with 
detergent then wiped with 100% ethanol. The vertical gel eletrophoresis tank was set 
up and the percentage of the polyacrylamide gel used depended on the size of the 
fragment of interest. For RPA assay, normally a 5% polyacrylamide gel was used. 
For a 25ml gel, 12.5% acrylamide : bisacrylamide (29: l ratio) was mixed with 10.5g 
urea and 2.5ml 10X TBE. Sufficient H2O was added to dissolve the urea and the 
solution filtered and topped up to 25ml with H2O. Before pouring the gel, 150µl of 
10% ammonium persulfate and 40µl Tetramethylethylenediamine (TEMED) were 
added to the gel solution to catalyze polymerization. The solution was immediately 
poured between the glass plates and a comb inserted. Once the gel had set, it was 
placed in the vertical electrophoresis tank with 1X TBE as running buffer. Before 
loading the samples, the gel was pre-run at 25mA for 30min. Samples were loaded, 
then electrophoresis continued at 250V for 2h. Following electrophoresis (when the 
dye reached the bottom of the gel), the gel was disassembled, transferred from the 
glass plate onto 3MM filter paper and dried under vacuum for 2h. The dried gel 
(covered in Saranwrap) was exposed to a phosphorimager screen (Fuji imaging 
plate) for 15min, which was then scanned in a Fuji BAS phosphorimager. mRNA 
levels were quantitated using Aida software (Advance image data analyzer Version 
3.44.035). A representative autoradiograph of a test RPA is shown in Fig 2.2. 
 
2.2.10 Realtime PCR 
cDNA was synthesized from RNA as described in section 2.2.11.1 and 
specific cDNA levels were measured using the Roche LightCycler 480 (Roche 
Diagnostic Ltd, Burgess Hill, West Sussex, UK). Initially, a test plate was carried 
out to assess the cDNA dilution needed and select the appropriate internal control. 
cDNA was pooled from each sample and an initial standard curve was produced by 
serial dilution of the pooled cDNA; neat, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:168 and 
1:336. Each sample was meaured in triplicate in a total reaction volume of 10µl; 5µl 
LightCycler 480 Probes Master mix, 4.5µl cDNA and 0.5µl Taqman® gene 
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expression assay (Applied biosystems). Dilution of the cDNA selected for 
measurement was chosen to give amplification at around 20-27 cycles. Appropriate 
internal controls (ß-actin, TBP or 18S) were selected for each individual experiment 
that showed no difference between the groups within that experiment.  
 
2.2.11 Competitive RT-PCR to determine relative abundance rat 
and mouse GR mRNAs 
2.2.11.1 cDNA synthesis 
For reverse transcription reactions, 2µg of RNA sample was diluted to 10µl 
with nuclease-free H2O (Promega) and incubated at 70°C for 10min to disrupt 
secondary structure. 10µl master mix (4µl MgCl2, 2µl 10x reverse transcription 
buffer (Promega), 2µl 10mM dNTP mix, 0.5µl recombinant RNasin® ribonuclease 
inhibitor (Progmega), 15U AMV reverse transcriptase, 0.5ug oligo(dT) primer) was 
added, with nuclease free water to a total of 20µl. Reactions were then incubated at 
42°C for 20min, 95°C for 5min and 4°C for 5min and stored at 4°C for later use. 
 
2.2.11.2 PCR reactions and PstI digestion of rat GR cDNA  
1µl of RT reaction was used in the PCR reaction. PCR reactions were carried 
out as described in section 2.11.1 with PstI digest primers (section 2.1.3). The PstI 
primers were an identical match to both rat and mouse GR cDNA and amplify a 
100bp PCR product from both. To distinguish rat GR PCR product from mouse, 
17µl of the PCR reaction  was  restricted  in  a  20µl  volume containing  2µl  10x  
restriction  buffer H  (Promega), 10U PstI (Promega) and digested at 37°C for 5h. 
The PstI digested PCR product gave a 49bp fragment. The undigested PCR product 
and the PstI-digested PCR product were assessed by electrophoresis on a 2.5% 
agarose gel (Section 2.2.12.1).  
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Figure 2.2 Optimization of RNase protection assay (RPA) 
Representative autoradiograph showing a test RPA used to assess the amount of sample RNA and RNase needed. (A) 6h exposure showing GR 
and actin (internal control) protected fragments. Lanes 1 and 2 contained reactions of probe (GR or actin; respectively) with no RNase.  Lane 3-
14 all contain reactions digested with 1/25 dilution of RNase T1. Lane 3 contained yeast tRNA, GR and actin probe (negative control). Lanes 4 
and 5 contained 10µg of mouse liver RNA with probe (GR or actin; respectively) with RNase T1. Lanes 6-14 contain various concentrations of 
liver or Sc RNA extracted from a non-tg mouse (Lanes10;11 and 12;13 contain RNA from adipose tissue of 2 difference mice). In sach case, 
the RNA was made to a total of 10ug with yeast tRNA. Lanes 15-17 contained 10µg of liver RNA with various dilutions of RNaseA/T1 (1/50, 
1/100, 1/200; respectively) L= ladder. (B) Graph showing a linear relationship between the levels of GR and actin products obtained from 
phosphoimager quantification of the gel shown above. 
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2.2.12 Recombinant DNA techniques 
2.2.12.1 Restriction enzyme digests and gel electrophoresis 
For optimal enzyme digestion, different enzyme buffers (supplied with the 
enzyme) were used for different enzymes. A typical 15µl enzyme digest contained 
1.5µl 10x enzyme buffer, 1µl (10U) enzyme, 5-10µg DNA of interest. The 
DNA/enzyme mixture was then incubated at 37ºC for 1h.   
The percentage of agarose gel made depended on the size of DNA fragment 
of interest. Agarose was dissolved in 0.5 x TBE or 1 x TAE and dissolved by boiling 
in a microwave. For every 100ml of agarose gel, 2µl of ethidum bromide (10mg/ml) 
was added. Molten agarose was poured into a gel tray containing an appropriately 
sized comb, to set. The gel was then placed into an electrophoresis tank filled with 
0.5 x TBE or 1 x TAE. DNA samples were mixed with 1µl loading dye and loaded 
onto the gel, 1 kb ladder was loaded in parallel. The gel was then run at 70-100V for 
~1h untilthe fragment of interest was separated by electrophoresis. For excision of 
DNA the band was visualized under UV light at 360nm. For analytical digest, DNA 
was visualized at 260nm. DNA fragments for cloning or microinjection were 
separated by electrophoresis in 0.8-1.5% (depending on the size of fragment to be 
extracted) low melting point agarose gels in 1x TAE. The fragment of interest was 
visualized at 360nm, excised from the gel and extracted using a Qiaex II agarose gel 
extraction kit (Qiagen). 
 
2.2.12.2 Filling in 3’ or 5’ overhang DNA ends 
 For filling in 3’ recessed ends following restriction enzyme digest, reactions 
were adjusted to 1x HindIII restriction buffer and 0.25mM dNTPs added together 
with 2-3 U Klenow enzyme. Reactions were incubated at room temperature for 
15min and terminated by heating at 75ºC for 15min. For the 3’ overhangs, Klenow 
was added first without dNTPs and incubated at room temperature for 15min (to 
remove the 3’ overhang). dNTPs were added as above and the reaction continued as 
above. 
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2.2.12.3 Removal of 5” phosphate from DNA 
 For digestion with CIP, restriction enzyme reactions were diluted >2 fold 
with TE (to reduce NaCl content below 25mM), then 1U of CIP was added and the 
reaction incubated at 37ºC for 5min. The enzyme was inactivated by incubation at 
65ºC for 15min. 
 
2.2.12.4 Ligation of DNA 
 Ligations typically contained 0.5-2µg DNA, comprising vector and insert in a 
~1:3 molar ratio, and were carried out in 10µl with 1 x T4 ligase buffer (supplied 
with the enzyme) and 1U of T4 DNA ligase for sticky end ligation or 3-5U for blunt 
end. Ligations were incubated at 12-15ºC for up to 48h.  
 
2.2.12.5 Transformation 
Prior to the transformation, competent cells were made. A single HB101 
colony was selected from a plate and placed into 2ml of LB then incubated in a 
shaking incubator at 37ºC for 16h. 0.5ml of this starter culture was then diluted into 
50ml LB then incubated in a shaking incubator at 37ºC for ~1.5h to grow to mid log 
phase. The culture was centrifuged at 6K rpm (rotor JA20, Beckman J2-MC 
centrifuge) for 5min at 5ºC. The cell pellet was then resuspended in 20ml 0.1M 
CaCl2 and the suspension was placed on ice for 10min. The cells were then 
centrifuged at 6K rpm (rotor JA20, BeckmanJ2-MC) for 5min at 5ºC. The cell pellet 
was then resuspended in 2ml 0.1M CaCl2 and left on ice for ≥12h. For 
transformation, 200µl of competent cells were mixed with ~5µl of ligation mixture, 
left on ice for 20-30min, then heated at 42ºC for 50s before transferring to ice for 2-
3min. The cells were plated out on an LB/AMP plate and incubated at 37ºC for 
~16h.  
 
2.2.12.6 Plasmid prep (miniprep) 
 A single transformed bacterial colony was selected from the plate and placed 
into 2ml of LB containing 100µg/ml ampicillin then incubated in a shaking incubator 
at 37ºC for 8-16h to grow to late log phase. The culture was centrifuges at 13k rpm 
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(Heraeus, biofuge) for 1min at room temperature. The cell pellet was resuspended in 
100µl GTE, 200µl of alkaline/SDS solution was then added to lyse the bacterial cells 
and the suspension was placed on ice for 10min. 150µl of postassium acetate 
solution was added to the suspension mix, mixed well and placed on ice for a further 
15min. The suspension was spun at 13k rpm (Heraeus, biofuge) for 5min. The 
supernatant was transferred to a fresh tube and 450µl phenol/chloroform (1:1) added, 
vortexed, 400µl of the aqueous (upper) layer was transferred to a fresh tube and 1ml 
ethanol added to precipitate the DNA. After 1min, the precipitated DNA was 
collected by centrifugation at 13l rpm (Heraeus, biofuge) for 2min. The pellet was 
air-dried at room temperature, then resuspended in 50µl TE buffer, 1µl RNase A (20 
µg/ml). 
 
2.2.12.7 Plasmid prep (maxiprep) 
A single transformed bacterial colony was selected from the plate and placed 
into 2ml of LB containing 100µg/ml ampicillin then incubated in a shaking incubator 
at 37ºC for 6h to grow to late log phase. This starter culture was then added to 500ml 
LB containing 100µg/ml ampicillin and grown overnight with shaking at 37ºC. The 
culture was centrifuged at 6k rpm (rotor JA14, Beckman J2-MC centrifuge) for 5min 
at 4ºC. The cell pellet was then resuspended in 12ml of GTE. To lyse the bacterial 
cells, 25ml of alkaline/SDS solution was added and the suspension placed on ice for 
10min.  16ml of potassium acetate solution was added to the suspension, shaken well 
to mix and placed on ice for a further 10min.  The cell lysate was centrifuged at 6k 
rpm (rotor JA14, Beckman J2-MC) for 10min and the supernatant filtered through 
gauze to remove floating precipitate. Plasmid DNA was precipitated from the 
supernatant by the addition of 32ml isopropanol followed by incubation at room 
temperature for 30min. The precipitated DNA was collected by centrifugation at 10k 
rpm (rotor JA14, Beckman J2-MC) for 3min. The pellet was air-dried at room 
temperature for 2h, then resuspended in 2.2ml of TE. 3g CsCl and 100µl Ethidium 
Bromide (10mg/ml) were then added and the suspension transferred to a heat-seal 
ultracentrifuge tube. It was then centrifuged at 70k rpm (rotor TLK 100.3, Beckman 
Optima™ TLX ultracentrifuge) for 18h. The ethidium bromide stained band 
containing plasmid DNA was extracted through the side of the tube using a syringe 
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and needle, transferred to a fresh tube and topped up with TE/CsCl solution made by 
adding exactly 1g of CsCl to each 1ml TE. The DNA prep was centrifuged again at 
70k rpm (rotor TLK 100.3, Beckman Optima™ TLX ultracentrifuge) for 16h or at 
100k rpm for 4h. The plasmid band was removed as before, ethidium bromide 
extracted from the DNA with repeated isopropanol extractions (until no more pink 
color was detectable) and plasmid DNA dialysed against several changes of TE over 
24h. 
 
2.2.13 Transfection of mammalian cells 
 B103 neuroblastoma cells (Steinbach, Schubert et al. 1974) were kindly 
provided by V. Kelly. Cells from two 75cm2 flasks were harvested by centrifugation 
at 1k rpm (Heraeus labofuge 400R) for 5min at room temperature. The pellet was 
resuspended in 15ml fresh medium (DMEM containing 10% foetal calf serum 
(FCS), 100U/ml penicillin and 100U/ml streptomycin). The cell number was 
determined using a hameocytometer and the volume of cells adjusted to give a final 
concentration of 3 x 105 cells/ml.  1ml of the resuspended cells was placed in each 
60mm dish with 3ml of medium and incubated overnight at 37ºC, 5% CO2. The 
medium was replaced 1h prior to transfection. For each transfection, a DNA mix was 
made consisting of 37µl 2M CaCl2 and 10µg DNA adjusted to 300µl with H2O. 
20min prior to transfection, the DNA mixture was slowly added with agitation to 
300µl of 2xHBS; a fine precipitate was formed. This transfection mixture was 
incubated at room temp for 15min, then added dropwise to a dish of cells. The cells 
were incubated with the transfection mixture overnight. The next day, the medium in 
each dish was replaced with fresh medium and again incubated overnight. The 
following day, transfected cells were harvested; medium was removed carefully 
from each dish and cells were washed in 3ml of PBS. 300µl of lysis buffer was then 
added to each dish and left for 15min. Lysed cells were scraped from each dish and 
centrifuged at 13k rpm for 1min at room temperature in a microfuge. Both luciferase 
and β-galactosidase assays were carried out on aliquots of lysates.  
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2.2.13.1 Luciferase assay 
 Assays were carried out in duplicate. Each tube contained 5µl 100mM ATP 
pH7.0, 100µl luciferase assay buffer and 40µl lysate. Light emission was read in a 
luminometer (Berthold) following injection of 105µl 1mM luciferin.  
 
2.2.13.2 β-galactosidase assay 
 Assays were carried out in duplicate using a commercial kit (Galacto-light 
kit, Tropi, Bedford MA). Each tube contained 67µl 1/100 dilution galacto reaction 
buffer (supplied with the kit) and 10µl of lysate. Reactions were incubated at room 
temperature for 20 min and light emission measured using a luminometer (as above) 
which injected 105µl acceleration solution (supplied with the kit). 
 
2.2.14 Creation of the aP2-GR construct  
 pGL3-basic (Promega) was used as the vector for the construct. The initial 
cloning steps were carried out by Val Kelly (creating all the pVL plasmids). First, 
pGL3-basic was restricted with SalI and ligated to a pair of complementary 
oligonucleotides of the following sequence: 5’-TCGAGCGGCCGCGTTTAAACG-
3’ and 3’-CGCCGGCGCAAATTTGCAGCT-5’ to create pVL295. This recreated 
the SalI site at one end only and also added NotI and PmeI restriction sites. Next, the 
SmaI-XbaI fragment of pVL295 was removed and ligated to rat GR cDNA to form 
pVL296; rat GR cDNA was encoded on a SalI–SspI (GR exon 2) fragment from 
pVL152 and a SalI-XbaI fragment from EGFP-rGR (Prima, Depoix et al. 2000) 
encoding the rest of rat GR cDNA. Finally, the aP2 enhancer/promoter was inserted 
in 2 stages; pVL296 was restricted with KpnI/SstI and ligated to a ~600bp KpnI-SacI 
fragment from paP2 (Ross, Graves et al. 1993) (a gift from B. Spiegelman) to form 
pJan1 (Fig.2.3). Next, pJan1 was restricted with Sst1, treated with calf intestinal 
phosphatase (CIP) to prevent religation of pJan1, and ligated to a 5000bp SstI aP2 
fragment   from  paP2  to  form  the  final  aP2-GR   construct  pJan2   (Fig.2.4).  The 
construct was verified using XbaI and EcoRV which generated the predicted 
fragments of 1876, 3200, 2750, 3660 and 918 and 8300b.p., respectively (Fig.2.5). 










Figure 2.3 Schematic diagram of the structure and the formation of pJan1 
Plasmid pJan1 was formed by sequentially (a) modifying the enzyme sites within 
pGL3 basic to add NotI and PmeI sites on a linker, creating PVL295*; (b) replacing 
the luciferase cDNA (LUC) with a KpnI-XbaI fragment encoding “sense” rat GR 
cDNA (PVL296*). Then (c) a KpnI-SacI fragment encoding a section of the aP2 
promoter enhancer/fragment (400bp) was added to the modified plasmid to create 
pJan1. *PVL 295 and 296 were created by Val Kelly. 









Figure 2.4 Schematic diagram of the structure and the formation of the Ap2-
GR transgene.  
Plasmid Ap2-GR was formed by SacI cleavage of pJan1 and insertion of a 5000bp 
SacI fragment from paP2 encoding the aP2 promoter/enhancer, to create pJan2. The 
transgene containing the fragment was then extracted by digestion with KpnI and 
PmeI. 




2.2.15 Creation of the SV40-GR construct 
To establish that the reconstructed GR cDNA was functional, a second 
construct was created using a similar approach. The aP2 enhancer/promoter in pJan2 
was replaced with the SV40 viral promoter/ enhancer from pJ3 (Morgenstern and 
Land 1990). pVL296 was linearised with NheI to generate a fragment of 5560bp 
which was blunt ended by fillinf in the ends with Klenow (section 2.2.11.2) then 
ligated to a 400b.p. PvuI-SmaI fragment encoding the SV40 promoter enhancer from 
pJ3. The resulting construct, pJan3 (Fig.2.6A) was verified using SalI/Xba double 
digest, which created fragments of 3300, 2200 and 480bp (Fig.2.6B). The construct 
was transfected into B103 cells, which have negligible endogenous GR (Freeman, 
Munn et al. 2004) to assay GR activity.  
 
2.2.16 Creation of aP2-GR founder mice 
A KpnI/PmeI double digest was used to isolate the 11kb aP2 
promoter/enhancer-GR fragment to be injected Chapter4. The 11kb fragment was 
excised from a gel and isolated using a Qiaex gel extraction kit (Qiagen) according 
to the manufacturer’s instructions. 10ng/µl of isolated fragment was microinjected 
into the pronuclei of C57BL/6J x CBA/C3H F1 embryos and placed into foster 
mothers to produce “Founder” mice, by the re-derivation service, University of 
Edinburgh. Transgenic founder mice were identified by PCR carried out on genomic 
DNA extracted from either ear or tail clips using PCR primers that span the junction 
between the aP2 fragment and the GR cDNA (unique to the transgene) which 
produce a 376bp PCR product.  Each of the founders was backcrossed to C57BL/6J 
mice to produce the F1 generation.  
Genotyping 
2.2.16.1 Genotyping of aP2-GR transgenic mice by PCR 
Genomic DNA was extracted from tail biopsies or from ear clips taken at 
weaning using a DNeasy® tissue kit (Qiagen) according to the manufactur’s
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Figure 2.5 Restriction digest to identify plasmid Ap2-GR  
Plasmid Ap2-GR (pJan2) was identified by restriction digest with (A) Xbal I (correct 
plasmid predicted to give fragments of 1876, 3200, 2750, 3660bp) and (B) EcoRV 
(correct plasmid predicted to give fragments of 918 and 8300bp). Each lane contains 
DNA from a different miniprep and lane marked “L” was loaded with 1kb ladder. 
*Indicates lanes in which the plasmid contains the correct predicted sized of 
fragments after digestion. 
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Figure 2.6 Schematic diagram of the structure and the verification of the SV40-GR construct 
(A) Plasmid SV40-GR (pJan3) was formed by digesting pVL296 with NheI, filling in the sticky ends with Klenow fragment of DNA 
polymerase I to form blunt-end linear DNA, 5” phosphates with CIP, then ligating to a SV40 promoter fragment extracted from pJ3 by 
digesting with PvuI and SmaI. (B) DNA gel verifying the plasmid which the plasmid which contained the correct predicted fragments of 
480, 2200 and 3300bp using SalI/Xbal double digest. * Indicated lanes in which the plasmid gives the correct predicted sizes of fragments 
after digestion. 
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instructions. DNA preparation from ear clips was identical to that from tail clips 
except that quantities were scaled down 10x.  
In order to minimize non-specific priming, Taqbead hotstart polymerase 
(Promega) was used. PCR reactions were carried out in 0.5ml PCR reaction tubes 
and contained 1mM dNTPs, 1.5mM MgCl2 (supplied with the polymerase), 1x 
polymerase reaction buffer (supplied with the polymerase), 0.1µM each primer 
(section 2.1.3), 1µl of genomic DNA and 1 Taqbead. The final volume of the PCR 
reaction was made to 50µl with ultra-pure H2O. Initial denaturation was 96ºC for 8 
min, then a total of 35 cycles of 94ºC 30s; 60ºC 90s; 72ºC 2 min were carried out, 
with a final incubation for 10 min at 72ºC. The aP2-GR primers amplify a 370 bp 
PCR product. Globin primers (section 2.1.2) , used as a positive control, amplify a 
480bp PCR product. PCR products were assessed by electrophoresis of 20µl of the 
reaction on a 1.2% agarose gel (section 2.10.1). 
 
2.2.17 Protein methods  
2.2.17.1 Western blot 
2.2.17.1.1 Protein extraction  
 For protein extraction, tissue samples were weighed and 50mg of tissue was 
homogenized in 600µl of protein extraction buffer. The homogenate was then 
centrifuged at 4k rpm (rotor F-45-11, Eppendorf microentrifuge 5415R) for 10min at 
4°C to remove any debris. The supernatant was then removed and 50µl aliquots 
frozen at -20°C for future use and protein quantification.  
 
2.2.17.1.2 Protein Quantification 
Protein concentration was determined using the Bio-Rad DC protein assay (Bio-
Rad). This is a colorimetric assay for protein determination. Sample concentrations 
were determined from a standard curve created from a series of dilutions of bovine 
serum albumin (BSA), ranging from 0-1.2mg/ml. To ensure all samples lay within 
the standard curve, a test assay was carried out using the most diluted sample within 
the set. This sample was compared with the highest protein standard (1.2mg/ml) 
using the Bio-Rad protein assay. Dilution was required if the sample shared a similar 
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or greater colour to the standard. All samples were diluted according to the test assay 
and measured in duplicate in a 96 well plate. 5µl of diluted sample or standard was 
added to each well followed by 50µl of reagent A then 200µl of reagent B. The plate 
was then incubated at room temperature for 15min before reading in a plate-reader 
spectrometer at 750nm (Molecular device, OPTImax). The protein concentration was 
then determined from the standard curve. 
 
2.2.17.1.3 Western analysis of protein  
   25µg of protein sample was adjusted to 6.5µl with H2O and added to 6µl of a 
pre-prepared mix of 5µl NuPAGE® LDS sample buffer (Invitrogen) and 1µl of 
NuPAGE® reducing agent (Invitrogen). Samples and 10µl of Plus2® pre-stained 
protein markers (Invitrogen) were incubated at 70ºC for 10min to denature the 
protein. Samples were loaded onto a 4-12% Bris-Tris Novex® pre-cast Gel 
(Invitrogen) which locked to the buffer core in a vertical electrophoresis tank. The 
inner chamber was filled with 200ml of 1x Novex® MOPs running buffer 
(Invitrogen) and 500µl of NuPAGE® antioxidant (Invitrogen) and the outer chamber 
filled with 600ml of 1x Novex® MOPs running buffer. Samples were 
electrophoresed at 200V until the bromophenol blue band had migrated to the 
bottom of the gel. The gel was then removed form the plastic cassette and proteins 
transferred from the gel to a nitrocellulose membrane using a wet transfer system. 
The transfer was set up as shown in Fig 2.7. Transfer was effected at 30V for 90min. 
Following transfer, the membrane was rinsed in H2O and left to dry on Whatman 
No.3 filter paper.  
 
2.2.17.1.4 Antibody binding to western blot 
To reduce non-specific antibody binding, the membrane was rehydrated with 
1xTBS for 5 min blocker (Bio-rad), 0.1% Tween) for 1h at RT or overnight at 4°C 
with agitation. The blocking solution was then removed and the membrane was 
incubated with primary antibody diluted in blocking buffer (GR 1:400 or tubulin 
1:5000) for 2h at room temperature with agitation. Next, the membrane was rinsed in 
blocking solution three times, each for 10min then incubated with agitation for 2h at 




Figure 2.7 Schematic diagram of western blot transfer setup 
Schematic diagram showing the wet transfer step of western blot used to transfer 
protein from SDS-PAGE gels to nitrocellulose membranes. 
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room temperature with secondary antibody diluted in blocker buffer. For the GR 
primary antibodies, the secondary antibody was goat anti-rabbit IgG-HRP (Santa-
Cruz) , used at a dilution of 1:5000; for the tubulin primary antibody, the secondary 
antibody was goat anti-mouse IgG-HRP (Santa Cruz), used at a dilution of 1:10,000. 
Finally, the membrane was rinsed in 1x TBS for 15min, followed by three washes in 
1x TBS, each for 5min. The secondary antibody was visualized by incubating the 
membrane in 1ml of ECL detection mix (equal volumes of reagents 1 and 2) for 
1min before exposing against autoradiographic film for a period of time between 5 
and 15min and then developing. Autoradiographs were scanned using ascanner and 
quantitated using Aida software (Advance image data analyzer Version 3.44.035). 
 
2.2.17.1.5 Peptide binding assay  
Mouse GR has a predicted molecular mass of ~86kDa, but migrates on SDS-
PAGE at ~95kDa (Hutchison, Dalman et al. 1993). To determine which specific 
band within the western blot represented GR, the primary antibody was preabsorbed 
with the peptide used as immunogen (PA1-512, Cambride Bioscience). Two tubes of 
primary antibody were prepared, a “control” tube containing 1µg GR antibody with 
2 ml of blocking solution and a “neutralized” tube containing 1µg GR antibody with 
4µg neutralizing peptide in 2ml of blocking solution. Both tubes were incubated with 
agitation at RT for 1h. The primary antibody was then applied to the two separate 
blots as described in 2.12.1.4. By comparing the “control” blot with the 
“neutralized” blot the GR immunoreactive band was identified. (Fig.2.8)  
 
2.2.18 Statistical analysis 
For statistical analysis of data obtained in this theses, 2 statistical software were 
used, Sigma Stat 3.1 and GraphPad Prism 5.  







Figure 2.8 Validation of the GR antibody 
To identify the GR immunoreactive band, the primary GR (PAI-512) antibody was 
preabsorbed against the peptide used to generate the antibody. Two identical western 
blots loaded with 30µg protein from liver (Liv) or Sc adipose tissue of non-
transgenic mice were probed (A) with GR antibody and (B) with GR antibody 
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3 The Effects of Dietary Fats on Peripheral 
Glucocorticoid Action 
Dietary fats are known to contribute to the development of obesity, 
hypertension, dyslipidemia and insulin resistance, collectively termed the metabolic 
syndrome. It appears that different types of dietary fatty acid can differentially 
impact on insulin sensitivity. In healthy humans, it has been shown that without 
altering total fat content, simply switching from a diet high in saturated fat to 
unsaturated fat results improves insulin sensitivity (Vessby et al 2001, Ricardi et al., 
2004). Furthermore, stearate (18:0) an abundant dietary long chain saturated fat 
inhibits insulin signaling in muscle cells, whereas myristate (C14:0) a short chain 
saturated fat, and oleate (18:1) a long chain unsaturated fat, do not exert such effects 
(Chavez and Summers 2002).  
Interestingly, a high fat diet regulates adipose 11β-HSD1 level (Morton, 
Ramage et al. 2004). Both acutely and chronically, mice fed high fat diet show a 
marked reduction in 11β-HSD1 mRNA levels and enzyme activity in all adipose 
depots (Morton, Ramage et al. 2004). It was suggested that the down-regulation of 
adipose tissue 11β-HSD1 expression upon high fat diet might be protective against 
obesity (Morton, Ramage et al. 2004), but the exact mechanism that caused this 
down-regulation was unclear. The work described in this chapter was designed to 
test the hypothesis that 11β-HSD1 and glucocorticoid receptor (GR) expression 
levels within adipose tissue are regulated by the composition of dietary fats.  To 
address this, mice were fed diets enriched in long-chain saturated, mono-unsaturated 
or poly-unsaturated fatty acids, and their effects on systemic corticosterone levels, 
glucose/insulin homeostasis and tissue 11β-HSD1 mRNA levels were investigated. 
3.1 Result 
3.1.1 Study 1: Pair Feeding of HF Diet; Experimental Design 
 Male C57BL/6J mice aged 6-8 weeks, n=12 per group, were housed in pairs 
under standard conditions with 12h light and 12h dark. Mice were given one of three 
different high fat diets; enriched in saturated (stearate, 18:0), mono-unsaturated 
(oleic, 18:1) or poly-unsaturated fat (safflower, 18:2). In order to allow comparison, 
all three diets contained the same kcal/g and % of fat (Table 3.1). In addition, a 
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control diet enriched in sucrose was selected which contained a lower % of fat and 
kcal/g (Table 3.1). To exclude an effect from different calorie consumption, all 
groups were fed ad libitum for a week with food intake monitored. The control 
sucrose group was found to consume the lowest calories. All diet groups were given 
calorie-matched diet daily, with continuous adjustment to the average intake for the 
control sucrose group, for 3 weeks. Weight gain and food intake were monitored and 
recorded every day. At the end of the experiment, mice were culled at 2 time points; 
morning (8am) and evening (8pm). This approach was used to allow an insight into 
the effect of diet on circadian rhythm (plasma hormones) and the HPA axis.  
 
3.1.1.1 Effect of HF diet upon body weight 
During the first week of the study, when all groups were allowed ad libitum 
access to food, the control group had the lowest energy (kcal) intake (Fig 3.1). 
Therefore, for the remaining 3 weeks, all the other groups were pair-fed to the 
control group. Throughout the study, the stearate group routinely consumed all the 
food within 16 h, while all the other groups had food remaining at the time of 
monitoring and food replenishment (data not shown). 
 At the end of the experiment, the mean body weight of stearate-fed mice was 
15% less than control diet-fed mice (Fig 3.2). The mean body weight of the group 
fed safflower oil enriched diet was highest throughout the study, but was not 
significantly different to the control diet group (Fig 3.2). The body weight of the 
oleic acid-fed group was similar to the control diet group (Fig 3.2).  
To assess any differences in adipose tissue distribution and weight, the 
mesenteric (Mes), subcutaneous (Sc), epididymal (Epi), retroperitoneal (RP) and 
brown adipose depots (BAT) were dissected and weighed. In addition, kidney, liver 
and adrenal gland were dissected and weighed to assess changes in other organs 
possibly affected by diet. There were no differences in adipose tissue or organ 
weights between the control, safflower and oleic acid fed-groups, whether the 
animals were killed in the morning or the evening (Fig 3.3). However, in the stearate 
group, adipose tissue weights were significantly lower than in the control group (Fig 
3.3). No differences were seen in any of the organ weights measured in the morning.
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Figure 3.1 Caloric intake during the first week of the high fat diet  
Total calorie intake per mouse in week 1. Control (■), Stearate (■), oleic acid (■) 
and safflower oil (■) Data are expressed as mean ± SE (n=6). **P<0.01, ***P < 
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Figure 3.2 Longitudinal body weights 
Body weight of mice fed control diet (●) or diets enriched in stearate (●), oleic acid (●) or safflower oil (●) during the entire 4 weeks of 
the study which included 1 week of free access to food to assess food intakes followed by 3 weeks of pair-feeding to the control group. 
*P<0.05, **P<0.01, ***P < 0.001, compared to control diet (two way RM ANOVA). Data are mean body weight of each group ± SEM.  




Figure 3.3 Effect of diets on adipose tissue and organ weights 
Weights of adipose tissues from mice on control (■), stearate (■), oleic acid (■) and 
safflower oil (■) diets. Data from mice killed at 8am (A) or at 8pm (B). Data are 
mean ± SEM; * P<0.05, **p<0.01 ANOVA, compared to control diet. 
Adipose tissues were: Subcutaneous (Sc), Epididymal (Epi), Mesenteric (Mes), 
Retroperitoneal (RP), Brown adipose tissue (BAT) 
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However, the liver weighed significantly more in the stearate group killed in the 
evening compared to the control diet group (Fig 3.3). 
 
3.1.1.2 Effect of pair-feeding high fat (HF) diets upon plasma 
hormone levels 
To determine the effect of the different HF diets upon plasma hormone 
levels, plasma corticosterone (Cort) and insulin levels were measured. In the 
morning, at the nadir level of Cort, the stearate group had 10-fold increased Cort 
levels compared to the control group (Fig 3.4A). Morning Cort levels in the oleic 
acid and safflower oil-fed groups were similar to the control group (Fig 3.4A). 
Although there was a trend for the oleic acid and safflower oil groups to have lower 
plasma Cort levels in the evening than the control group, this was not significant (Fig 
3.4B). 
Morning plasma insulin levels in the stearate group were significantly lower 
than in the control group (Fig 3.5A). Apart from that, there were no other significant 
differences between plasma insulin levels either in the morning or in the evening 
(Fig 3.5). Fasting plasma glucose levels were not different between groups, either in 
the morning or the evening (Fig 3.6). 
 
3.1.1.3 Effect of HF diets upon 11β-HSD-1 mRNA and activity levels 
in adipose tissue   
To assess whether any of the HF diets affected 11β-HSD1 expression, levels 
of 11β-HSD1 mRNA were measured by northern analysis of RNA isolated from 
Mes, Sc and Epi fat depots as well as liver. In addition, 11β-HSD1 enzyme activity 
was measured in homogenates of adipose tissues and liver (by Lynne Ramage). No 
group differences were seen between morning and evening 11β-HSD1 mRNA levels 
in Sc fat (Fig 3.7A). However in Epi fat, in the oleic acid fed group,11β-HSD1 
mRNA levels were significantly higher in the evening compared to the morning 




Figure 3.4 Consequence of high fat diet on plasma corticosterone level 
Plasma Cort levels at 8am (A) and 8 pm (B) with control group (■), stearate group 
(■), high oleic acid group (■) and safflower oil group (■). Data are expressed as 
mean ± SE (n=6).    *P < 0.05, ANOVA, compared to control diet. 
 




Figure 3.5 Consequence of high fat diet on plasma insulin levels 
Plasma insulin levels were measured in control (■), stearate (■), high oleic acid (■) 
and safflower oil-fed groups (■) under basal conditions at 8am (A) and 8pm (B). 
Data are expressed as mean ± SE (n=6), **P < 0.005, ANOVA, compared to control 
diet. 
 





Figure 3.6 Consequence of high fat diet on fasting glucose levels 
Fasting plasma glucose levels were measured in Control (■), stearate (■), oleic acid 
(■) and safflower oil (■) groups at 8am (A) and 8pm (B). Data are expressed as 
mean ± SE (n=6). There were no significant difference (1-way ANOVA) between 
groups. 
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Figure 3.7 Effect of high fat diet on 11β-HSD1 mRNA expressions 
11β-HSD1 mRNA levels were measured in control (■), stearate (■), oleic acid 
(■) and safflower oil-fed (■) groups killed at 8am (dark bars) or 8pm (light bars). 
11β-HSD1 mRNA levels were measured relative to 18S RNA and are expressed as 
% of control killed at 8am, arbitrarily set to 100%. 11β-HSD1 activity assays were 
performed by L. Ramage. 11β-HSD1 activity is expressed as % conversion of 
substrate (Cort) to product (11dehydro cort). Data are expressed as mean ± SE 
(n=6); with mice on control diet arbitrarily set to 100%. * indicates a significant 
difference (ANOVA) between the indicated groups with **P< 0.01. 
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(Fig 3.7B). In addition, in Epi fat, morning 11β-HSD1 mRNA levels in the stearate 
group were increased compared to the control group  (Fig 3.7B).  In  the  evening,   
all  3high fat groups exhibited a similar level of 11β-HSD1 mRNA expression in Epi 
fat to the control group (Fig 3.7). There were no differences between groups or am 
versus pm in 11β-HSD1 mRNA levels in mes adipose tissue (Fig 3.7C)In the three 
fat depots, there were no differences between 11β-HSD1 enzyme activity measured 
in the morning and evening, within each diet group (Fig 3.8). However, an increase 
in 11β-HSD1 activity was observed in the stearate-fed group compared with the 
control diet-fed group, in all 3 depots (Fig 3.8).  
In all three depots, 11β-HSD1 activity in the morning was significantly 
higher in the stearate-fed group than in the oleic acid-fed group (Fig 3.8). A similar 
pattern was also observed between the stearate- and safflower oil-fed groups, with 
higher 11β-HSD1 activity in the stearate group. However, the difference between 
stearate- and safflower oil-fed groups only achieved significance in the Sc and Epi 
fat depots (Fig 3.8). 
3.1.1.4 Effect of HF diets upon GR and 11β-HSD1 mRNA levels in 
liver  
To determine the effect of HF diet on glucocorticoid action within liver, GR 
and 11β-HSD1 mRNA levels were measured (Fig 3.9). Within each diet group, a 
significant difference between 11β-HSD1 mRNA levels in morning and evening was 
observed in both the stearate–fed and oleic acid-fed groups; in the stearate group, a 
2-fold increase in 11β-HSD1 mRNA expression was found in the evening compared 
to the morning. However, the reverse pattern was observed in the oleic group, with a 
significant decrease in 11β-HSD1 mRNA in the evening compare to the morning 
(Fig 3.9A). In the evening, 11β-HSD1 mRNA levels in the stearate group were 3-
fold higher than the control group (Fig 3.9A). Although a similar pattern of 
expression of GR mRNA was observed, none of the differences were significant (Fig 
3.9B). 
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Figure 3.8 Effect of high fat diet on 11β-HSD1 activity in adipose tissues 
11β-HSD1 enzyme activity were measured in control (Con)(■), stearate (ST)(■), 
high oleic acid (HO)(■) and safflower oil (SA)(■) groups killed at 8am (solid bars) 
or 8pm (spotted bars). 11β-HSD1 activity assays were performed by L. Ramage; 
11β-HSD1 activity is expressed as % conversion of substrate (Cort) to product 
(11dehydro-cort).  
Data are expressed as mean ± SE (n=6); with mice on control diet arbitrarily set to 
100%. * indicates a significant difference (ANOVA) between the indicated groups 
with **P< 0.01. 








Figure 3.9 Effect of high fat diet on 11β-HSD1 and GR mRNA expression in 
liver  
Both HSD1 mRNA expression (A) and GR mRNA expression was measured in mice 
fed in control diet (■) or diets enriched in stearate (■), High oleic acid (■) or 
safflower oil (■) in both 8am (dark bars) and 8pm (light bars). mRNA expression 
was measured relative to 18s RNA and is expressed as % of control killed at 8am, 
arbitraity set to 100%. Data are expressed as mean ± SE (n=6). ** P<0.01 
(ANOVA). 
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3.2 Study 2: Ad libitum Feeding of HF diet: Aims and design 
Study 1 showed that diets enriched in different fatty acids resulted in 
alterations in glucocorticoid action. However, the results were limited by the 
possible adverse effect of pair-feeding, particularly in the stearate group which lost 
weight during the study. Furthermore, none of the groups showed the down-
regulation of adipose 11β-HSD1 activity previously observed in mice fed a 58% fat 
diet (mixed fat content) compared with an 11% fat (cornstarch-enriched) control diet 
(Morton, Ramage et al. 2004). Therefore a second study was carried out, in which 
diets were fed ad libitum to rule out the effect of calorie restriction. Additionally, in 
this study, to rule out a difference between control diets (cornstarch versus sucrose-
enriched) both control diets were included. For comparison with the original study 
(Morton, Ramage et al. 2004), the same 58% fat diet (mixed fat) was selected. To 
exclude effects due to differences in % of kcal as fat, a 45% fat (mixed fat, identical 
composition to the 58%) diet was also selected. This 45% fat diet contains the same 
% of fat as the selectively enriched fatty acid diets used in study 1. Mice (n=6/group) 
were allowed ad libitum access to food throughout the study, which was carried out 
over 4 weeks. Body weight and food intake were recorded daily. Five days prior to 
the end of the experiment, blood was taken in the evening to measure plasma 
corticosterone levels. Three days prior to the end of the experiment, mice were fasted 
for 6h and blood was taken for measurement of fasting plasma glucose and insulin. 
This approach would allow an insight into insulin sensitivity. At the end of the 
experiment, mice were sacrificed in the morning, and blood was taken for 
measurement of plasma corticosterone levels. Tissue was collected as described in 




3.2.1.1 Effect of ad libitum feeding HF diet upon body weight 
After 4 weeks of ad libitum feeding, the body weight of the sucrose-enriched 
control group did not differ from the cornstarch-enriched control group. Mice fed 
oleic acid, safflower oil, 45% fat or 58% fat diets all gained significantly more body
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weight than the control groups (Fig 3.10). Despite consumption of comparable 
amounts of calories, stearate-fed was the only group which lost weight during the 
study (Fig 3.10 and 3.11). 
To assess any difference in adipose tissue distribution and weight, adipose 
tissues were dissected as described in Study 1. In addition, liver and kidney were 
also dissected as described in Study 1. There were no differences in adipose tissue or 
organ weights between the two control groups fed cornstarch or sucrose diets (Fig 
3.12). In mice fed oleic acid or 58% fat diets, Sc, Epi and Mes fat depot weights 
were significantly greater than in the control cornstarch group (Fig 3.12). In contrast, 
in the stearate group, the Sc, Epi and Mes fat, weights were significantly lower than 
the cornstarch control group (Fig 3.12). Fat weight in the other groups (safflower oil 
or 45% fat) did not differ significantly from the cornstarch control group (Fig 3.12). 
No differences were seen in brown adipose tissue or organ weights between the 
groups (Fig 3.12).  
 
3.2.1.2 Effect of ad libitum feeding HF diet upon plasma glucose 
hormone levels 
 In order to assess the effect of diet upon glucose homeostasis, fasting plasma 
insulin and glucose levels were measured (Fig 3.13). No differences in fasting 
plasma glucose/insulin levels were seen between the control sucrose and the control 
cornstarch group (Fig 3.13B). Compared to the cornstarch control group, the 
stearate-fed group had significantly lower fasting plasma insulin and glucose levels 
(Fig 3.13A), whereas, mice fed the oleic, safflower and 58% fat diets all showed a 
significant increase in both fasting insulin and glucose levels, suggesting a tendency 
towards insulin resistance (Fig 3.13A). 
 No difference in plasma corticosterone levels was seen between the 
control sucrose and the control cornstarch group either in the morning (nadir) or 
evening (peak) (Fig 3.14). Compared to the control cornstarch group, the oleic acid 
safflower oil, 45% fat and 58%-fat fed groups showed suppressed morning plasma 
corticosterone levels (Fig 3.14A). Peak plasma corticosterone (Cort) levels did not 
differ in any group compared to the control cornstarch group (Fig 3.14B). However, 


































































































































































































































































































Figure 3.11 Food intake measured throughout the ad libitium diet study 
Food intake (kcal/gmBW/Day) was measured on mice fed Control cornstarch diet (■), control sucrose diet (■), stearate diet (■), high 
oleic acid diet (■), safflower oil-enriched diet (■), 45% fat diet (■) and 58% fat diet (■) between day 1-37. Data are expressed as mean 
± SE (n=6). There were no significant differences in food intake between groups 
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Figure 3.12 Effect of high fat feeding on organ and adipose tissue weights 
Weights of adipose tissue and organs from mice fed control cornstarch (■), control 
sucrose (■), stearate (■), high oleic acid (■), safflower oil (■), 45% fat (■) or 58% 
fat (■) diets. Data are expressed as mean ± SEM (n=6). *P<0.05, ***P<0.001, 
compared to control cornstarch diet (ANOVA). 




Figure 3.13 Effect of high fat feeding on plasma insulin and glucose level 
The relationship between fasting plasma glucose and insulin levels (A) and 
glucose/insulin ratio (B) in mice fed control cornstarch (■), control sucrose (■), 
stearate (▲), high oleic acid (■), safflower oil (▲), 45% fat (●) and 58% fat (●) 
diets. Data are expressed as mean ± SE (n=6). *P < 0.05, compared to control diet 
(one way ANOVA followed by Dunnett post hoc test). 





Figure 3.14 Consequence of high fat diet on plasma corticosterone level 
Plasma corticosterone levels in the morning (8am; A) and in the evening (8pm; B) in 
mice fed control cornstarch (■), control sucrose ( ■ ), stearate (▲), high oleic acid 
(■), safflower oil (▲), 45% fat (●) and 58% fat (●) diets. Data are expressed as 
mean ± SE (n=6), a= significantly different from each other, P < 0.05, compared 
each other (one way ANOVA followed by Dunnett post hoc test). 
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a trend for lower plasma Cort levels was observed in the 45% fat fed group 
compared to the control sucrose group (Fig 3.14B). Among the high fat diet groups, 
the stearate group had 2-fold higher peak plasma Cort levels than the 58% fat group 
(Fig 3.14B).  
 
3.2.1.3 Effect of ad libitum feeding HF upon 11β-HSD1 mRNA and 
activity levels in adipose tissue   
To assess the effects of the HF diets on 11β-HSD1, northern analysis was 
used to measure levels of 11β-HSD1 mRNA in Mes and Sc fat depots as well as 
liver. In addition, 11β-HSD1 enzyme activity was measured in homogenates of 
adipose tissues and liver (by Lynne Ramage).  
In both Sc and Mes fat, 11β-HSD1 mRNA levels did not differ in mice fed 
control cornstarch or control sucrose diet (Fig 3.15A). In Sc fat, 11β-HSD1 mRNA 
levels were significant higher in the stearate group compared to the control 
cornstarch group (Fig 3.15A).  In contrast, all the other HF diet groups showed a 
marked reduction in 11β-HSD1 mRNA levels compared to the control cornstarch 
group (Fig. 3.15A). This effect paralleled similar changes in 11β-HSD1 activity 
levels (Fig. 3.15B). In Mes fat, compared to the control cornstarch group, no 
differences were observed in mice fed stearate, oleic acid or safflower oil diets (Fig. 
3.16). However, both the 45% fat and 58% fat groups showed a significant decrease 
in 11β-HSD1 mRNA expression in Mes fat (Fig. 3.16A). In Mes fat, 11β-HSD1 
activity was significantly increased in the control sucrose and the stearate diet 
groups, compared to the control cornstarch group (Fig. 3.16B). Despite the reduction 
in 11β-HSD1 mRNA levels, no difference in 11β-HSD1 activity was observed in the 
45% fat group, nor did 11β-HSD1 activity, differ in the oleic acid or safflower oil 
groups (Fig. 3.16B). However, the 58% fat group showed a significant reduction in 
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Figure 3.15 Consequence of high fat diet on subcutaneous fat 11β-
HSD1 mRNA expression and activity levels  
Subcutaneous fat (A) 11β-HSD1 mRNA expression and (B) 11β-HSD1 activity in 
mice fed control cornstarch (■), control sucrose ( ■ ), stearate (▲), high oleic acid 
(■), safflower oil (▲), 45% fat (●) and 58% fat (●) diets. Data are expressed as 
mean ± SE (n=6) *P<0.05, **<0.01, ***P < 0.001, compared to control cornstarch 
diet (one way ANOVA followed by Dunnett post hoc test).





Figure 3.16 Consequence of high fat diet on mesenteric fat 11β-HSD1 
mRNA expression and activity levels 
Mesenteric fat (A) 11β-HSD1 mRNA expression and (B) activity in mice fed control 
cornstarch (■), control sucrose ( ■ ), stearate (▲), high oleic acid (■), safflower oil 
(▲), 45% fat (●) and 58% fat (●) diets. Data are expressed as mean ± SE (n=6) 
*P<0.05 compared to control cornstarch diet (one way ANOVA followed by 
Dunnett post hoc test). 
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Figure 3.17 Consequence of high fat diet on subcutaneous fat and mesenteric fat 
GR mRNA expression 
(A) Subcutaneous fat and (B) mesenteric fat GR mRNA expression in mice fed 
control cornstarch (■), control sucrose ( ■ ), stearate (▲), high oleic acid (■), 
safflower oil (▲), 45% fat (●) and 58% fat (●) diets. Data are expressed as mean ± 
SE (n=6). There were no significant differences between groups. 
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3.2.1.4 Effect of ad libitum feeding HF upon GR mRNA levels in 
adipose tissues 
A major determinant of glucocorticoid action is glucocorticoid receptor 
density. GR mRNA levels in Sc, Mes fat were measured using real-time PCR. There 
was no significant effect of diet on GR mRNA levels in any of the tissues examined 
(Fig. 3.17). 
3.3 Discussion 
3.3.1 Study 1 
Over the study period (28 days), all diet groups were adjusted to the same number of 
calories consumed by the group that consumed the least calories in the first week of 
the study; the control group. Under these pair-fed conditions, diets enriched in 
different dietary fats caused a differential variation in body weight and fat 
distribution in mice. The stearate group showed an unexpected weight loss from day 
21, whereas the high oleic acid group maintained a high body weight throughout the 
study. Furthermore, the stearate group killed in the morning exhibited significantly 
smaller Sc, Mes and Epi fat depot weights but normal liver weight. Whilst the mice 
killed in the evening showed the same trend for lighter mes fat compared to control, 
thus not significant while their livers were significantly heavier compared with 
control-fed mice. This dramatic increase in liver weight followed soon after feeding 
(diet was provided at ~3pm) and may reflect “binge” eating in the stearate group. 
This is supported by plasma corticosterone levels, which were 10 fold markedly 
elevated in the stearate group in the morning compared to control mice. However, 
this difference was diminished in the evening, consistent with the high morning 
levels being due to fasting. Plasma insulin levels in the stearate group were low in 
the morning, but high in the evening; 7 fold increased over levels in control mice. 
The high evening insulin levels could be a postprandial effect and low morning 
insulin levels could result from fasting, as the stearate-fed mice consumed their food 
very rapidly compared to other groups (data not shown).  
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Figure 3.18 Consequence of high fat diet on liver 11β-HSD1 and GR mRNA 
expression. 
Liver (A) 11β-HSD1 mRNA levels, (B) 11β-HSD1 activity and (C) GR mRNA 
levels in mice fed cornstarch (■), control sucrose (■), stearate (▲), high oleic acid 
(■), safflower oil (▲), 45% fat (●) and 58% fat (●) diets. Data are expressed as 
mean ± SE (n=6), ***P < 0.001, compared to control diet. *P<0.05, **P < 0.01, 
compared to control diet (one way ANOVA followed by Dunnett post test). 
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Dietary fat intake altered 11β-HSD1 activity and mRNA levels in adipose 
tissue. Compared to the control group, stearate-fed mice killed in the morning 
showed a significant increase in 11β-HSD1 activity in all three fat depots 
(subcutaneous, epididymal and mesenteric). If this is not an effect of the constituents 
of the diet, this up-regulation of 11β-HSD1 activity in the stearate group could be the 
result of overnight fasting as it was not so marked in stearate-fed mice in the 
evening. A trend to down-regulation of adipose 11β-HSD1 activity in mice fed diets 
enriched in oleic acid and safflower oil was found in all three fat depots but this did 
not reach significance. These groups also showed a trend toward higher weight gain, 
suggesting that the HF-mediated down regulation of 11β-HSD1 previously reported 
could be related to weight gain. In contrast to 11β-HSD1, GR mRNA levels in Sc 
and Mes fat of stearate-fed mice killed in the morning were decreased compared to 
control mice. An inverse relationship between 11β-HSD1 and GRmRNA has been 
described in human adipose tissue (Michailidou, Jensen et al. 2007). However, an 
inverse relationship between adipose GR and 11β-HSD1 mRNA levels was not 
observed in adipose tissue of mice fed high oleic acid or safflower oil diets.  
In addition to adipose tissues, the pattern of GR and 11β-HSD1 mRNA 
expression in the liver was also examined. With the exception of the stearate group, 
the different diets regulated 11β-HSD1 mRNA levels in the opposite direction to that 
observed in the adipose tissue, as previously observed (Morton, Ramage et al. 2004). 
However, none of the differences in 11β-HSD1 or GR mRNA levels between diet 
groups in the morning achieved significance. In contrast, a 3-fold increase in 11β-
HSD1 mRNA expressions was observed in the stearate group killed in the evening. 
This marked increase could result from binge eating. More interestingly, the trend to 
lower levels of 11β-HSD1 and GR mRNA in liver in the evening, seen in the 
control, high oleic and safflower oil enriched diet groups was reversed in the group 
fed stearate. To fully understand these effects, it will be important to determine the 
effect of stearate diet on metabolism, as stearate diet was the only diet to alter liver 
weight (but only PM) suggesting an acute effect on liver function. In addition, 
malabsorption of stearate diet is also a consideration as stearate-fed mice exhibited 
significant gut hypertrophy (data not shown). This could indicate an altered 
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absorptive state in order to extract nutrients from a highly saturated fat diet-enriched 
meal.  
This study was designed to test which constituents of a HF diet are 
responsible for down-regulation of adipose 11β-HSD1. Accordingly, three diets 
differing in their fatty acid composition – saturated, mono-unsaturated and poly-
unsaturated fat were compared. Although none produced the expected down-
regulation, a trend towards down-regulation of adipose 11β-HSD1 was observed in 
the high oleic acid and safflower oil-fed group. This suggested that mono-saturated 
or poly-saturated fat might be responsible, but none of the effects were significant, 
so no conclusions are possible.  
Data in this study have shown a complex interaction between circulating 
glucocorticoid, peripheral 11β-HSD1 activity and GR mRNA expression. However, 
Study 1 differed from previous studies in two important respects: (1) these high fat 
diets contained just 45% compared to the previous study which contained 58% 
(Morton, Ramage et al. 2004). (2) The calorie intake within the study was restricted 
to be the same as the control diet. In addition, the mixed fat content within the 
original 58% fat diet might also be responsible for the down-regulation of 11β-HSD1 
activity. Therefore, it was necessary to conduct a second study which allowed ad 
libitum access to all diets and which included additional HF diets. 
 
3.3.2 Study 2 
To investigate some of the questions arising from the Study 1; the ad libitum 
feeding study was carried out. Three additional diet groups were also included, the 
58% mixed-fat diet and the control cornstarch diet used in the original HF study, and 
a 45% mixed-fat diet. Recent studies have suggested that diets enriched in sucrose 
suppress HPA axis activity (Pecoraro, Reyes et al. 2004) and also affect peripheral 
GC action (Dallman, Pecoraro et al. 2005).  
Whilst the control cornstarch and the control sucrose diet produced 
comparable effects on the majority of the parameters measured, they differed in their 
effects on 11β-HSD1 activity, but not mRNA levels. Enzyme activity was higher in 
the sucrose diet group in Sc fat and Mes fat, with the opposite pattern being seen in 
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liver to that found in adipose tissue. Consistent with previous studies (Morton, 
Ramage et al. 2004; Drake, Livingstone et al. 2005), 58% mixed-fat down-regulated 
adipose tissue 11β-HSD1. The results were apparent in this study after 4 weeks 
following either 45% or 58% mixed-fat diet, although the magnitude of the effect 
was smaller with 45% mixed-fat diet than 58% mixed-fat diet. This suggests that the 
% of fat within the diet, whilst influencing the outcome but itself was not causing the 
down-regulation. However, the composition of the diet could be an important factor, 
Oleic acid produced similar effects to the 58% mixed-fat diet, suggesting that the 
mono-unsaturated fat may be the major factor constituent causing the down-
regulation. However, safflower oil enriched diet also down-regulated 11β-HSD1, so 
the question of exactly which component within diet actually regulated 11β-HSD1 
still remains to be answered. 
As in study 1, the most pronounced dietary effects were observed in the 
sterate-fed group. Stearate diet resulted in weight loss (Fig. 3.11) and an improved 
glucose homeostasis. These results are not consistent with other’s observations that 
saturated fats cause insulin resistance (Chavez and Summers 2003). In addition, the 
stearate diet caused significant elevations in 11β-HSD1 activities in both Sc and Mes 
fat depots although 11β-HSD1 mRNA levels were elevated only in Sc fat and not 
Mes fat. A similar variance between 11β-HSD1 activity and mRNA levels were also 
found between intact preadipocytes visceral adipose tissue and in human visceral 
adipose tissue (Goedecke, Wake et al. 2006; De Sousa Peixoto, Turban et al. 2008), 
suggesting there might be regulation of enzyme activity at the post-transcriptional 
level. In addition, this discrepancy could be depot-specific as visceral fat has been 
shown to be less sensitive towards the effect of insulin.  
The effect of stearate goes against the hypothesis that high adipose HSD1 
levels always associate with obesity and insulin resistance (Seckl, Morton et al. 
2004). The weight loss in the stearate fed-group suggests that this result observed 
with pair feeding (Study 1) was not entirely due to insufficient food (fasting) but 
included another mechanism (e.g. malabsorption) (Sampath and Ntambi 2005). In 
humans, it was found that stearate is less effectivly absorbed by the gut (Sampath 
and Ntambi 2005). It is possible that the stearate diet used here was not completely 
absorbed and mice were in a state of caloric restriction. A fecal assay for signs of 
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malabsorption may be necessary to investigate whether this is a cause of weight loss 
in the sterate group. This would be consistent with the significant weight loss, the 
low levels of plasma insulin and the elevated plasma corticosterone levels. 
Furthermore stearate has been shown to be a poor substrate for TG synthesis 
(Sampath and Ntambi 2005). In future investigations, an alternative short chain 
saturated fat such as palmitate could be used.  
In this study, the 58% fat diet resulted in the biggest weight gain.  
Interestingly, a comparable body weight gain was observed in the oleic acid fed 
group containing just 45% calories as fat. In addition, both the 58% fat and oleic acid 
groups expressed an altered glucose homeostasis suggestive of insulin resistance, 
accompanied by low circulating corticosterone levels and significantly reduced 11β-
HSD1 mRNA and activity in Sc fat. Thus, the 45% oleic acid diet caused many of 
the same effects as the 45% and 58% mixed-fat diets.  
In the future, it would be of interest to measure the level of PPARγ mRNA 
expression within these HF diet groups as PPARγ has been shown to regulate both 
adipocyte differentiation and adipocyte 11β-HSD1 levels (Beaven and Tontonoz 
2006; Sharma and Staels 2007).  Further investigations could be carried out by 
including essential fatty acids (omega 3 and 6) in the diets as both omega 3 and 6 
polyunsaturated fatty acids have been shown to have beneficial effects upon insulin 
sensitivity and they reduce cardiovascular risk (Harbige 2003, Lee et al.,2006). In 
addition, the effect of sucrose and other carbohydrates would be worth investigating 
given the role in obesity of carbohydrates like corn syrup, fructose and foods that are 
highly processed and energy-dense (Fried and Rao 2003). These studies would allow 
us a better understanding of the impact of different diets on the development of 
obesity and metabolic syndrome. 
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4 The effects of adipose GR density on peripheral 
glucocorticoid action 
 
 In order to test the hypothesis that adipose GR density is an important 
determinant of adipose acquisition in diet-induced obesity, it is necessary to 
specifically alter GR density in adipose tissues. To do this, transgenic mice were 
created in which the adipocyte-specific aP2 enhancer/promoter drives expression of 
rat glucocorticoid receptor. The “sense” rat GR cDNA is ~80% identical to mouse 
GR cDNA and a similar “sense” rat GR cDNA has previously been used to 
overexpress GR, in β cells under the control of the insulin promoter (Delaunay, 
Khan et al. 1997) and in thymus under the control of the p56 proximal Lck promoter 
(Pazirandeh, Xue et al. 2002). In addition, transgenic mice in which the aP2 
enhancer/promoter was used to drive an “antisense” rat GR cDNA (to reduce 
adipose GR levels) were characterized. 
 
4.1 Results 
4.1.1 Construction and validation of an aP2-GR “sense” 
transgene 
 The aP2-GR construct was assembled by ligating restriction fragments from 
a plasmid encoding the 5.4kb aP2 enhancer/promoter (Ross, Graves et al. 1993) 
(provided by B. Spiegelman) to the rat GR cDNA as described in Methods section 
(Chapter 2, section 2.2.13). The final construct structure is shown in Fig. 4.1A. As 
the GR cDNA was assembled from several fragments it was necessary to verify that 
it was functional.  For transfection, modification of the construct was needed, as the 
aP2 promoter only functions in adipocytes which are not readily transfectable. 
Accordingly, the aP2 promoter region was replaced by the SV40 viral 
promoter/enhancer which is active in many cell types creating the plasmid pJan3 
(Capter 2, section 2.2.14). B103 neuroblastoma cell (Schubert et al, 1974) have 
negliglible levels of GR mRNA but glucocorticoid responsiveness is restored by 
transfection with exogenous GR (Freeman, Munn et al. 2004). In order to test 
whether the rat GR cDNA within the construct was functional, B103 cell were co-
transfected with pJan3 or pRS-hGR (Giguere, Hollenberg et al. 1986) encoding 




Figure 4.1 Construct used to generate aP2-GR “sense” transgenic mice 
(A) The final construct structure of the aP2-GR “sense” transgene, consists of the 
aP2 promoter driving rat GR cDNA. (B) Transfection result validating the rat GR 
cDNA used within the construct. The aP2 promoter was exchanged for an SV-40 
promoter to generate pSV-rGR (pJan3) (Chapter 2, section 2.2.14). Transfection of 
pSV-rGR (pJan3) into B103 cells showed that it resulted in a greater dexamethasone 
induction than vector only.  pSV-GR gave  a similar level of response to pRSV-hGR 
(encoding human GR), which was used a positive control. Data are mean ± SEM of 
3 independent transfections for each construct.  
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human GR as a positive control and MMTV LTR-luc, a glucocorticoid responsive 
promoter linked to a luciferase reporter gene (Lefebvre, Berard et al. 1991). 
Transfected cells were cultured in the presence or absence of 10-6M dexamethasone. 
In the presence of dexamethasone, transfection of pJan3 resulted in a 30-fold 
increase in MMTV LTR activity, similar to the increase in promoter activity in cells 
transfected with pRS-hGR (Fig. 4.1B). This demonstrated that the rat GR cDNA 
used in the construct is functional.    
                                                                                                                                      
4.2 Generation and breeding of aP2-GR transgenic mice 
4.2.1 Generation of aP-2GR mice  
 The purified transgene fragment was microinjected into the pronuclei of 
fertilized C57BL/6 x CBA/C3H F1 embryos by the re-derivation service, University 
of Edinburgh. After microinjection, a total of 55 mice were obtained from 5 pregnant 
females. The presence of the transgene was detected via PCR on genomic DNA 
extracted from tails (Fig 4.2). 5 founder mice were identified; 3 male (numbers 15, 
32, 33) and 2 female (numbers 17 and 26).  
Founder (G0) mice were backcrossed to C67BL/6J mice to establish lines. Of 
the five founders, only four (15, 17, 26 and 32) produced offspring. However, line 26 
only managed to produce transgenic offspring for the first generation and the 
transgene was not transmitted to the second generation. Line 15 did not produce any 
transgenic offspring when crossed to C57BL/6, so lines 17 and 32 were selected for 
breeding. Of the two selected lines, line 32 consistently gave a stronger intensity 
transgene PCR product (Fig. 4.2 and data not shown).  To distinguish between the 
two lines, line 17 and 32 were renamed B-FSG and D-FSG, respectively. 
 




Figure 4.2 Representative gels showing PCR genotyping of founder aP2-GR 
transgenic mice 
Founder transgenic mice carrying the rat aP2-GR transgene were identified by PCR 
using primers which specifically amplify a 376 bp fragment of rat GR. A 494 bp 
PCR product of β-globin was also amplified as a positive control for the presence of 
DNA.  “L” represents lanes loaded with 1kb ladder and “Water” were negative 
controls containing water instead of DNA. PCR reactions on DNA from mice no. 6, 
12, 13, 14, 15, 16, 17, 18, 19, 26, 32, 33, 25, 17, 21 22 and 23 were loaded in the 
indicated lanes. * Indicates the presence of a product from rat GR in mice mice no. 
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4.3 Characterization of B- and D-FSG mouse lines 
4.4 Transgene expression in adipose tissue 
4.4.1 Rat GR mRNA is expressed in both B- and D-FSG mice  
 To determine whether the rat GR transgene is expressed in adipose tissue, 
custom real-time PCR assays were developed by Dr. Elaine Marshall. Mouse and rat 
GR cDNA show 80% homology (http://nrr.georgetown.edu/grr/seqcomp.html). To  
distinguish between rat and mouse mRNA, a gene region unique to mouse GR was 
selected for the mouse GR primer-probe set and a gene region specific for the rat GR 
was selected.    
Levels of rat GR mRNA and mouse GR mRNA were measured using real-
time PCR in adipose tissues (subcutaneous, gonadal and mesenteric depots) and liver 
of transgenic (tg) mice (F1 backcross to C57BL/6J) and their non-transgenic (non-tg) 
littermates. Liver GR mRNA levels served as a control, as aP2 is not normally 
expressed in liver and therefore the transgene was not predicted to be expressed in 
liver.  
In both sexes of D-FSG tg mice (F1 generation), rat GR mRNA was present 
in all adipose tissues; subcutaneous (Sc), gonadal (Gon) and mesenteric (Mes), 
compared to the low levels detected in non-tg mice (probably due to cross-reactivity 
of the rat assay with mouse GR mRNA) (Fig. 4.3A and Fig. 4.4A). No differences 
were seen in hepatic GR mRNA levels between tg and non-tg mice with either the 
rat-specific or the mouse-specific real time PCR assay (Fig. 4.3 and Fig. 4.4), and 
mRNA detected by the rat GR assay in liver is likely to be due to cross-reactivity 
with mouse GR mRNA.  
In B-FSG, only female mice were examined. In tg mice  (F1 generation) 
when compared to non-tg littermates, rat GR mRNA was clearly present in Sc, Gon 
and Mes adipose tissues with very low level or none rat GR mRNA found in brown 
adipose tissue (BAT) or liver (Fig. 4.5A). In addition, levels of endogenous mouse 
GR mRNA did not differ in adipose tissue or liver between tg and non-tg mice (Fig. 
4.5B).  
         
 98 
 
Figure 4.3 Transgenic aP2-GR mice express rat GR mRNA specifically in white 
adipose tissue of 4-5 month old female mice (line D-FSG) 
Levels of (A) rat GR mRNA and (B) endogenous mouse GR mRNA were measured 
in non-tg (white) and tg (black) 4-5 month old female D-FSG (F1 generation) mice 
(n=4/group). GR mRNA levels are expressed relative to the internal control 
cyclophilin A and are reported in arbitrary units (AU). Data are mean ± SEM; and 
were analysed by 2-way ANOVA; *P<0.05 Data generated by Dr. Elaine Marshall. 
Abbreviations: SC; subcutaneous,  Gon; gonadal, Mes; mesenteric and Liv; liver  
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Figure 4.4 Transgenic aP2-GR mice express rat GR mRNA specifically in white 
adipose tissue of 4-5 month old male mice (line D-FSG) 
Levels of (A) rat GR mRNA and (B) endogenous mouse GR mRNA were measured 
in non-tg (white) and tg (black) 4-5 month old male D-FSG (F1 generation) mice 
(n=4/group). GR mRNA levels are expressed relative to the internal control 
cyclophilin A and are reported in arbitrary units (AU). Data are mean ± SEM; and 
were analysed by 2-way ANOVA; *P<0.05 Data generated by Dr. Elaine Marshall. 
Abbreviations: SC; subcutaneous,  Gon; gonadal, Mes; mesenteric and Liv; liver  
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Figure 4.5 Transgenic aP2-GR mice express rat GR mRNA specifically in white 
adipose tissue of 4-5 month old female mice (line B-FSG) 
Levels of (A) rat GR mRNA and (B) endogenous mouse GR mRNA were measured 
in non-tg (white) and tg (black) 4-5 month old female B-FSG (F1 generation) mice 
(n=4/group). GR mRNA levels are expressed relative to the internal control 
cyclophilin A and are reported in arbitrary units (AU). Data are means ± SEM; and 
were analysed by 2-way ANOVA; *P<0.05 Data generated by Dr. Elaine Marshall. 
Abbreviations: SC; subcutaneous, Gon; gonadal, Mes; mesenteric and Liver; liver  
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4.4.2 Increased adipose tissue weight in transgenic female D-FSG 
mice  
To assess any difference between tg and non-tg littermates in adipose tissue 
weight and distribution, various adipose tissues; subcutaneous (Sc), gonadal (Gon), 
mesenteric (Mes), perirenal (Per), retroperitoneal (RP) and brown adipose tissue 
(BAT) from B and D-FSG mice were dissected and weighed. In addition, liver (Liv) 
and kidney (Kid) were also dissected and weighed as control tissues where no effect 
of transgene is predicted within these organs.  
In male D-FSG (F1 generation; 5-6 month old) mice no difference in body weight 
was found between genotypes (non-tg, 35.4±1.3g vs tg, 34.26±1.8g, n=4/group)., In 
addition there were no differences in weights of adipose tissues  kidney or liver (Fig. 
4.6A). However, in female D-FSG (F1 generation; 5-6 month old) mice, the body 
weight of the tg mice was 11% heavier than their non-tg littermates (non-tg, 
22.0±0.6g vs tg, 24.8±0.9g, n=5/group) and the mice showed a significant increase in 
weight of white adipose tissues (Sc, Gon and Mes) with no difference in weight of 
BAT, kidney or liver, compared to non-tg littermates (Fig 4.6B).  
 In female, B-FSG (F1 generation, 4-5 month old) mice, there was no 
difference in tissue weight (Sc, Gon, Mes, Per, RP, BAT, kidney and liver) after 
correction to liver weight which showed no difference between non-tg and tg mice 
(non-tg, 1.02±0.05g vs tg, 1.01±0.04g, n=4/group) (Fig 4.7).  
 
4.5 Effect of transgene on response to HF diet 
As the preliminary characterization showed adipose-specific expression of 
the rat GR transgene and demonstrated the predicted increase in adipose tissue 
weight, although only in female of the higher copy number line (D-FSG), the effects 
of transgene upon response to diet-induced obesity were investigated in D-FSG 
mice. 
 
4.5.1 Experimental design 
 A 6 month high fat diet study was carried out during which blood pressure 
and metabolic parameters (glucose and insulin tolerance, plasma glucose and 
triglyceride level) were measured (Fig. 4.8).  




Figure 4.6 Sex-specific effect of aP2-GR transgene on adipose tissue weight in 
line D-FSG mice 
Weights of adipose tissues and organs of non-tg (white) and tg (black) 4-5 month old 
(A) male (n=4/group) and (B) female (n=5/group) D-FSG (F1 generation) mice. Data 
are expressed as tissue weight (g) relative to body weight (g). Body weight was not 
different between genotype in male D-FSG mice (non-tg, 35.4±1.3g vs tg, 
34.3±1.8g) but was significantly difference in female D-FSG mice (non-tg, 
22.0±0.6g vs tg, 24.8±0.9g; t-test; p<0.05). Data are means ± SEM and were 
analysed by 2way-ANOVA; **p<0.01, compared to non-tg littermates.  
Abbreviations: SC; subcutaneous, Gon; gonadal, Mes; mesenteric, Bat; brown 
adipose tissue. 





Figure 4.7 No significant effect of aP2-GR transgene on adipose tissue weights of 
line B-FSG mice 
Weights of adipose tissues and organs from non-tg (white) and tg (black) female 
4-5 month old B-FSG (F1 generation) mice. Data are expressed as ratio of adipose 
tissue or kidney weight relative to liver weight (arbitrarily set to 1 for each group) 
and are means ± SEM (non-tg n=6, tg n=4). Liver weight was not different 
between genotypes (non-tg, 1.02±0.05g vs tg, 1.01±0.04g). Data were analysed by 
2-way ANOVA; no statistically significant differences in adipose tissue or kidney 
weights were found between genotypes. 
 
Adipose tissues were: subcutaneous (Sc), gonadal (Gon), mesenteric (Mes), 
perirenal (Per), retroperitoneal (RP) and brown adipose tissue (BAT). 




Figure 4.8 Scheme showing experimental design 
Male and female tg and non-tg littermates (F2 generation; n=12/group) were weaned onto either high fat (HF) (58% kcal as fat) or low 
fat (LF) cornstarch-enriched diet (11% kcal as fat) and were allowed ab libitium access to food throughout the study. Body weight 
and food intake was monitored and recorded weekly. In a subgroup of mice (n=6/group), blood pressure was measured weekly for 10 
weeks. At 20 weeks of the study, glucose tolerance tests were carried out (n=6/group) and at 24 weeks, insulin tolerance tests were 
carried out (n=6/group). One week prior to the end of the study, mice were fasted for 24h and blood was taken for assay of plasma 
free fatty acid and triglyceride levels.   At the end of the study (27 weeks), mice (n=6) were culled in the morning (7:00 – 9:00 am), 
blood was collected for plasma corticosterone assay, adipose tissues (Sc, Gon, Mes, RP and BAT), tail (to confirm genotype), kidney, 
adrenal, liver were taken and stored at -80C for later analysis. In order to examine fat cell size, the remaining mice (n=6) within the 
group were culled and adipose tissues and liver placed in formalin for histology. 
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4.5.2 D-FSG Transgenic mice showed normal weight gain and 
tissue weights on HF diet 
High fat (HF) diet increased body weight gain in both male and female mice 
as expected (Fig. 4.9). HF diet increased mean body weight by ~50% for both 
genotypes, in both sexes (Fig. 4.9). However, no effect of transgene was observed in 
HF or LF fed diet groups at the end of the study (Fig. 4.9). Furthermore, no 
difference in food intake (g) was observed between genotypes, for either diet or sex 
(data not shown). 
There was no effect of transgene on adipose tissue or organ weights in either male or 
female mice, although there was a significant effect of diet on adipose tissue weight 
in all groups (Fig. 4.10).  In addition, no difference in adrenal weight was found in 
HF or LF diet-fed group of either sex (Fig. 4.11).   
  
4.5.3 Blood pressure in D-FSG mice was unaffected by transgene 
 To investigate the effect of high fat diet on blood pressure in D-FSG mice, 
blood pressure was measured from week 15 of the study; weekly blood pressure 
measurements were monitored for the following 10 weeks. No difference in blood 
pressure was observed between genotypes for either sex and either diet, although 
HF-fed mice exhibited higher blood pressure in both sexes compared to mice fed LF 
diet (Fig. 4.12 and 4.13). 
 
4.5.4 HF diet caused insulin resistance in both tg and non-tg D-
FSG mice 
 To investigate the effect of transgene on glucose homeostasis, glucose 
tolerance tests and insulin tolerance tests were carried out. Fasting plasma glucose 
levels were measured prior to glucose or insulin injection at time 0 and repeated 15, 
30, 60 and 120 min after the injection. In glucose tolerance tests (GTT), glucose 
intolerance was observed only in male HF-fed mice but no differences between 
genotypes were seen in plasma glucose levels of either sex on either diet (Fig. 4.14).   
Consistent with the GTT results, insulin tolerance tests (ITT) showed no difference  
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Figure 4.9 D-FSG transgenic mice showed normal weight gain on both HF and 
LF diets 
Longitudinal body weight of D-FSG mice (F2 generation) tg or non-tg mice fed 
either LF diet or HF diet, (A) male and (B) female mice. Mice were fed experimental 
diet from weaning (at 3 weeks of age) to the end of the study (28 weeks of age). Data 
are means ± SEM, n=12/group. 2-way repeated measure ANOVA showed a 
significant effect of diet from wk 13 of the study in both sexes (P<0.001), but no 
effect of genotype in either sexes. 
Key: Male non-tg LF (■), male tg LF (■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF(■), female non-tg HF (■) and female tg HF(■). 
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Figure 4.10 Effect of diet on adipose tissue and organ weights in D-FSG 
transgenic mice 
Adipose tissue and organ weights of D-FSG (F2 generation) tg and non-tg mice fed 
LF diet or HF diet (A) male and (B) female. Data are expressed as % of body weight 
and are mean ± SEM. 2 way ANOVA showed a significant effect of diet in both 
males and females (p<0.0001) but no significant effect of genotype in either sex. 
Adipose tissues were: subcutaneous (Sc), gonadal (Gon), mesenteric (Mes), 
retroperitoneal (RP) and brown adipose tissue (BAT) 
Key: Male non-tg LF (■), male tg LF(■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF(■), female non-tg HF (■) and female tg HF(■).
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Figure 4.11 No effect of diet or transgene on adrenal weight in D-FSG 
transgenic mice 
Adrenal weights of D-FSG (F2 generation) non-tg and tg mice fed LF diet or HF diet.  
(A) male and (B) female mice. Data are mean tissue weights ± SEM (n=6/group). 2-
way ANOVA showed no significant effect of diet or genotype in either male or 
female mice.  
Key: Male non-tg LF (■), male tg LF (■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF (■), female non-tg HF (■) and female tg HF(■). 








Figure 4.12 No effect of genotype on blood pressure in male D-FSG transgenic 
mice fed either LF or HF diet 
Weekly blood pressure measurements of male D-FSG (F2 generation) non-tg and 
tg mice fed (A) LF diet or (B) HF diet. Data are expressed as mean arterial 
pressure ± SEM, (n=6/group) Repeated measures 2 way ANOVA showed no 
effect of genotype or diet. 
Key: Non-tg LF (■), tg LF (■), non-tg HF (■) and tg HF (■) 
 
A 
B HF diet 
Blood Pressure of male D-FSG mice 
LF diet 







Figure 4.13 No effect of genotype on blood pressure in female D-FSG transgenic 
mice fed either LF or HF diet 
Weekly blood pressure measurements of female D-FSG (F2 generation) non-tg 
and tg mice fed (A) LF diet or (B) HF diet. Data are expressed as mean arterial 
pressure ± SEM, n=6/group. Repeated measure 2 way ANOVA showed no 
statistically significant difference between genotypes.   
Key: Non-tg LF (■), tg LF (■), non-tg HF (■) and tg HF(■).
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Figure 4.14 Glucose tolerance test in D-FSG mice 
Glucose tolerance test (GTT) in 25-27 week old D-FSG (F2 generation) mice fed 
LF or HF diet; (A) male and (B) female. For GTT, mice were fasted for 6h; blood 
was collected 0 and 15, 30, 60 and 120 min after intraperitoneal injection of 
glucose (2mg/g body weight) at time 0. Data are expressed as mean plasma 
glucose level ± SEM, n=6/group. Data were analysed by repeated measures 2 way 
ANOVA and showed no statistically significant differences between genotypes. 
Key: Male non-tg LF (■), male tg LF (■), male non-tg HF (■), male tg HF (■), 






Glucose tolerance test (Female) 







Figure 4.15 Insulin tolerance test in D-FSG transgenic mice 
Insulin tolerance test (ITT) in 25-27 week old D-FSG (F2 generation) mice fed LF 
or HF diet (A) male and (B) female mice. For ITT, mice were fasted for 6h; blood 
was collected 0, 15, 30 and 60 min after intraperitoneal injection of insulin (male; 
1.5mU/g BW, female; 1mU/g BW) at time 0. Data are expressed as mean plasma 
glucose level ± SEM, n=6/group. Data were analysed by repeated measures 2-
way ANOVA and showed no statistically significant differences between 
genotypes. 
Key: Male non-tg LF (■), male tg LF (■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF (■), female non-tg HF (■) and female tg HF 
(■). 
Insulin tolerance test  (Male) 
Insulin tolerance test  (Female) B 
A 
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between genotypes in plasma glucose levels following insulin injection, in either sex 
or on either diet (Fig. 4.15). 
 
4.5.5 Effect of transgene upon liver triglyceride levels in D-FSG 
mice 
 To investigate the effect of transgene on the level of triglyceride, liver 
triglyceride was measured. In males, liver triglyceride levels did not differ between 
tg and non-tg mice. However, both HF diet groups exhibited a 2-fold increase in 
liver triglyceride levels compared to LF diet groups (Fig. 4.16A).  No difference was 
found in female liver triglyceride level between genotypes on either diet (Fig. 
4.16B). 
 
4.5.6 Adipocyte size in D-FSG mice was unaffected by transgene 
To investigate the effect of transgene on adipocyte size, fixed and embedded 
Sc adipose tissue was sectioned (5µm sections) and stained with hematoxylin and 
eosin. No gross difference in adipocyte size was apparent between genotypes in both 
sexes (Fig. 4.17 and 4.18). However, increased adipocyte sizes were found in both 
sexes of HF fed mice compared to LF-fed mice (Fig. 4.17 and 4.18).      
 
4.5.7 Unaltered body weight in 1 year old transgenic female B- 
and D-FSG mice  
Due to the lack of phenotype in the dietary study carried out on the F2 D-FSG 
mice, the adipose tissue phenotype was reinvestigated in 1 year old F1 generation 
female mice of both lines. Adipose tissues; subcutaneous (Sc), gonadal (Gon), 
Mesenteric (Mes), retroperitoneal (RP) and brown adipose tissue (BAT), liver (Liv) 
and kidney (Kid) were collected and weighed. In 1 year old B-FSG F1 generation 
female mice, no body weight or adipose tissue weight difference was found between 
tg and non-tg littermates (Fig. 4.19 A and B). In 1 year old D-FSG females, although 
no difference in body weight was found between genotypes (non-tg, 28.68±2.3 vs tg, 




Figure 4.16 Unaltered liver triglyceride levels in D-FSG transgenic mice 
Liver triglyceride levels in 28 week old D-FSG (F2 generation) non-tg and tg mice 
fed LF diet or HF diet. (A) male and (B) female mice. Data are expressed as mean ± 
SEM; n=6/group. ANOVA showed significant effect of diet in males (p<0.001) but 
no significant effect of genotype in either sex. 
Key: Male non-tg LF (■), male tg LF (■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF(■), female non-tg HF (■) and female tg HF(■). 
 
  







Figure 4.17 Similar adipocyte histology between non-tg and tg male D-FSG 
mice 
Representative images of H and E stained sections of Sc adipose tissues from 29 
week old male D-FSG (F2 generation) mice. (A) LF diet, non-tg, (B) LF diet, tg 


















Figure 4.18 Similar adipocyte histology between non-tg and tg female D-FSG 
mice 
 
Representative images of H and E stained sections of Sc adipose tissues from 29 
week old female D-FSG (F2 generation) mice. (A) LF diet, non-tg, (B) LF diet, tg 






























Figure 4.19 No effect of aP2-GR transgene on body weight and tissue weight of 
1 year old female B-FSG mice 
(A) Body weight and (B) adipose tissue and organ weights of non-tg (white) and 
tg (black) female 1 year old female B-FSG (F1 generation) mice  (non-tg, n=4; tg, 
n=5). Data are means ± SEM; no significant differences were found in body 
weight or tissue weights. 
Abbreviations: SC; subcutaneous, Gon; gonadal, Mes; mesenteric, RP; 
retroperitoneal, BAT; brown adipose tissue  
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Figure 4.20 Significant effect of aP2-GR transgene on adipose tissue weight but 
not on body weight of 1 year old  female D-FSG mice 
 (A) Body weight and (B) weight of adipose tissues and organs of non-tg (white) and 
tg (black) 1 year old female D-FSG (F1 generation) mice  (non-tg, n=6; tg, n=5). 
Data are means ± SEM; analysed by (A) t-test, (B) 2-way ANOVA; *p<0.05, 
compared to non-tg littermate. 
Abbreviations: SC; subcutaneous, Gon; gonadal, Mes; mesenteric, RP; 
retroperitoneal, BAT; brown adipose tissue  





Figure 4.21 aP2-GR transgene did not affect plasma corticosterone levels in 
female D-FSG mice   
Plasma corticosterone (Cort) levels in 1 year old female non-tg (white) and tg (black) 
D-FSG (F1 generation) mice in the (A) morning (8am) and (B) evening (8pm). Data 
are means ± SEM (non-tg n=6, tg n=5); t-tests showed no statistically significant 
differences between genotypes. 
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33.64±2.0g; non-tg n=6, tg n=5) a significant increase was found in gonadal adipose 
tissue weight (Fig. 4.20).  
 
4.5.8 Unaltered plasma corticosterone levels in female D-FSG 
mice 
 In addition to body weight, both morning and evening plasma corticosterone 
were measured in 1 year old F1 generation D-FSG female mice. However, no 
difference was found between tg and non-tg littermates at both morning and evening. 
(Fig. 4.21) 
 
4.5.9 Variable rat GR expression was found in adipose tissue of 
both B- and D-FSG mice using a competitive RT-PCR assay 
Because real-time PCR had shown rat GR is expressed specifically in adipose 
tissues and a significant increase in adipose tissues was found in transgenic F1 
generation D-FSG females, the 24 week HF diet study was carried out on the F2 
generation of D-FSG transgenic mice as describe above. However, no phenotype 
was found in this study. In order to address the problem, competitive RT-PCR was 
carried out to semi-quantitatively assess transgene RNA expression relative to 
endogenous mouse GR mRNA. Adipose RNA was reverse transcribed and PCR was 
carried out using primers that amplify both rat GR and mouse GR cDNA. In order to 
distinguish rat GR from mouse GR, the PCR product was then digested using 
enzyme Pst1, predicted to only digest the rat GR DNA (Fig 4.22).  
GR mRNA in various adipose tissues depots of both B- and D-FSG at 
different generations was measured using competitive RT-PCR (Table 4.1). Variable 
GR expression was found in individual transgenic mice of either sex and amongst 
different generations (Table 4.1) 
 
4.5.10 RNAse Protection assay 
To determine the level of rat GR expression as well as total GR mRNA (rat 
and mouse) within adipose tissues, RNAse protection assays (RPA) were used. To 
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detect rat GR mRNA in mouse tissues a rat probe was used, which shares 80% 
identical sequence to mouse GR mRNA. RNAse T1 (cleaves at every mismatched G 
nucleotide in double stranded RNA) and RNAse A/T1 (cleaves at every mismatched 
C, T and G nucleotide) were used to measure total GR mRNA levels (endogenous 
mouse GR and rat transgene GR mRNA) or transgene-derived rat GR mRNA, 
respectively.  In addition, an actin probe was included as an internal control for RNA 
levels.  
RNA was extracted from adipose tissues of both B- and D-FSG mice of both sexes 
from generation F2-F8. A total of 19 RPAs were performed to try to establish 
whether rat GR was expressed in adipose tissues of B/D-FSG mice and the assays 
that were carried are summarized in Table 4.2. Two representative RPAs are shown 
in Fig. 4.23 and 4.24, respectively. In the experiment shown in Fig. 4.23, RNA 
extracted from Mes fat of B-FSG female mice was hybridized to the rat GR probe 
then digested using RNase A/T1. This resulted in protection of only rat GR mRNA. 
Upon 6h exposure, only a faint GR protected band was observed in the lane where 
rat liver RNA was used as a positive control (Fig. 4.23, lane 6), whereas actin 
protected fragments were observed in all the samples loaded indicating that the RNA 
was not degraded. Overnight exposure of the gel allowed better detection of the 
RNase A/T1 protected GR fragment (Fig. 4.23B). Again, although rat GR mRNA 
was detected in the positive control (rat liver RNA), no rat GR mRNA was detected 
in Mes fat in B-FSG mice (Fig. 4.23). In the representative experiment shown in fig. 
4.24, RNA extracted from Sc, Gon, BAT and liver of D-FSG (F1 generation) female 
mice was hybridized to rat GR cDNA and then digested with either RNase T1 (to 
detect total GR mRNA) or RNase A/T1 (to detect rat GR mRNA). No difference in 
total GR mRNA levels within adipose tissues was observed between genotypes nor 
was any rat GR mRNA detected within BAT or liver (Fig. 4.24C). 
 
4.5.11 Western Blot 
  In order to investigate any alteration in GR protein levels in the transgenic 
mice, western blotting was used. An antibody which identifies both rat and mouse 
GR was selected.  A representative western blot is shown in Fig. 4.25. GR protein 







Figure 4.22 PCR assay to detect experiment of rat GR mRNA 
Representative image of competitive RT-PCR reactions carried out on cDNA from 
Sc and Gon fat depots from male D-FSG (F1 generation) mice. The primers amplify 
both endogenous mouse and transgenic rat cDNA. On the left, undigested PCR 
product (96bp) arising from both mouse and rat GR mRNA. Only the rat PCR 
product contains a PstI site. On the right, PstI digested PCR product with the lower 
band sitting at 46bp representing the rat GR DNA product and the upper 96bp 
product, the undigested mouse PCR product. Numbers above the lanes are ID of 
individual mice; * indicates the mice which are transgenic. 










Table 4.1 Summary table of PstI digests to detect rat GR mRNA expression in 
aP2-GR transgenic mice 
Summary table of competitive RT-PCR on cDNA extracted from adipose tissues of 
various generations of B-FSG and D-FSG transgenic mice. Pst1 digestion was used 
after RT-PCR to distinguish rat GR from mouse GR.  +++, rat GR product shows 
stronger intensity than mouse GR product; ++, rat GR product shows similar 
intensity to mouse GR product; +, rat GR product shows less intensity than mouse 
GR product;  -, rat GR product is negligible or absent; ND, not done. 
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Figure 4.23 RNase protection assay (RPA) to measure rat GR mRNA levels in 
line B-FSG transgenic mice 
Representative autoradiograph showing rat GR mRNA levels in Mes fat of female 
line B-FSG (F1 generation) transgenic mice measured using RNase protection assay 
with RNase A/T1 digestion. Lanes 8-18 represent different mice with each lane 
loaded with a reaction containing 8µg RNA. (A) 6 hour exposure of GR protected 
fragment and the internal control actin protected fragment. (B) overnight exposure of 
the same gel to show GR fragment. No expression of rat GRmRNA was detected in 
any of the RNA samples from tg or non-tg mice. Lane 1 contained labeled markers, 
lanes 2 and 3 contained probe but no RNAse and lane 4 contained yeast tRNA 
instead of mouse RNA plus both rat GR and actin probes, which serves as the 
negative control. 
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levels in Sc fat of D-FSG F1 generation female mice were analysed and tubulin was 
used as internal control for the amount of protein being loaded. No differences in Sc 
GR protein levels were observed when tg were compared with non-tg littermates and 
the internal control (tubulin) indicated comparable levels of protein were loaded 
among all samples (Fig. 4.25B). Liver GR levels were also analysed using western 
blot and no difference was observed between tg and non-tg littermates (data not 
shown).   
 
4.6 Construction and characterization of transgenic mice 
expressing an aP2-antisense GR transgene 
 
aP2-anti-sense GR mice were generated by Elaine Marshall. These mice 
contained a transgene comprising the aP2 enhancer/promoter (as used for aP2-rat GR 
mice, described above) driving a portion of GR cDNA in the anti-sense direction. 
The region of rat GR cDNA chosen has been previously shown to reduce GR 
expression in transgenic mice (Pepin, Pothier et al. 1992; King, Vacchio et al. 1995). 
One line with the highest copy number was selected for further study. For ease of 
identification the line was named GR-5. Preliminary characterization showed female 
F1 generation transgenic GR-5 mice had reduced WAT mass (data not shown). 
However no phenotype was seen in male mice (data not shown). GR-5 (F2 
generation) transgenic mice were subject to the same HF diet experimental protocol 
as D-FSG mice. 
 
4.6.1 Female GR-5 transgenic mice showed lower body weight 
gain upon HF diet 
Body weights were measured throughout the study. In female mice fed LF 
diet, no difference in body weight was observed between genotypes (Fig. 4.26). 
However, HF-fed female tg mice showed reduced body weight gain compared to 
their non-tg littermates (Fig. 4.26). From week 19 onward the mean body weight of 
female GR-5 mice fed HF diet was significantly less than their non-tg HF-fed 
littermates (Fig. 4.26). At the end of the study, HF fed female GR-5 mice were 18% 
lighter than their non-tg HF fed littermates. Interestingly, in males no difference in 
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body weight was observed between genotypes in mice fed either HF or LF diet (Fig. 
4.26). 
 
4.6.2 Difference in adipose tissue weight upon HF diet in both 
sexes of GR-5 transgenic mice 
 To assess any differences in 
adipose tissue distribution and weight between genotypes, adipose tissues (Sc, Gon 
and Mes) were dissected and weighed. In addition, kidney and liver were dissected 
and weighed as before. No differences between genotypes in adipose tissue and 
organ weights were found in LF-fed mice in both sexes  (Fig. 4.27). However, 
following HF diet, a significant increase in Sc and Gon fat was found in GR-5 tg 
males compare to non-tg littermates (Fig. 4.27A). On the other hand, GR-5 tg female 
mice only shown a significant reduction in Sc fat weight (Fig. 4.27B and 4.28). 
 
4.6.3 No effect of transgene on glucose homeostasis  
 To investigate the effect of transgene on glucose homeostasis, glucose 
tolerance test were carried out. Fasting plasma glucose levels were measured as 
describe in section 4.4.4. In glucose tolerance tests (GTT), glucose intolerance was 
observed only in male HF-fed mice but no differences between genotypes were seen 
in plasma glucose levels of either sex on either diet (Fig. 4.29). Although a slightly 
improved glucose response was observed in tg female mice in both diet group, this 
was not significant when calculated using area under curve (LF non-tg, 42940±1988 
vs. LF tg 38710±758.8 g; non-tg n=6, tg n=6; HF non-tg, 55540±3171 vs. HF tg 
45620±4642 g; non-tg n=6, tg n=5). 
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Figure 4.24 RNase protection assay (RPA) to measure rat GR mRNA levels in 
line D-FSG transgenic mice 
Representative autoradiograph showing RPA to measure rat GR mRNA levels 
(RNase A/T1) and total GR mRNA levels (endogenous mouse and rat GR; RNase 
T1) in adipose tissue of female D-FSG (F5 generation) mice. (A) 6h exposure 
showing GR and actin (internal control) protected fragments and (B) overnight 
exposure of the same gel to show GR protected fragment.  Lane 1 contains labelled 
RNA marker, lanes 2 and 3 contain reaction with probe (GR or actin) but no RNase, 
lane 4 contains yeast tRNA instead of mouse RNA as negative control, lanes 7 and 8 
contain rat liver RNA as positive control. Lanes 9-16 contain RNA from adipose 
tissues of a single tg and non-tg mouse digested with RNase T1 as indicated. All 
reactions contained 8µg RNA. (C) Quantitative of GR/actin products from gel shown 
above. 
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Figure 4.25 Western blot to measure GR protein levels in Sc adipose tissue of 
female D-FSG (F1 generation) mice 
Representative western blots showing (A) GR and (B) tubulin levels in Sc adipose 
tissue of tg and non-tg D-FSG females (F1 generation). 30µg of protein was loaded 
in each lane except for lane 1 (60µg protein from Sc adipose tissue of non-tg mice). 
Lanes 2 and 3 contained 25µg and 12.5µg protein respectively, from liver of non-tg 
mice. The molecular weight marker is shown on the left of the blot. 
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Table 4.2 Summary table of RPA assay 
Summary table of RNA protection assays carried out on RNA extracted from 
adipose tissues of various generations of B-FSG and D-FSG transgenic mice, using 
T1 digestion to measure total GR mRNA level and A/T1 to measure rat GR mRNA 
level. The number within the table indicates the number of mice that were examined.  
✔; type of digestion carried out, ND; not done. 
 





Figure 4.26 Female GR-5 transgenic mice showed reduced weight gain upon HF 
diet 
Longitudinal body weight of tg or non-tg GR-5 mice (F2 generation) fed either 
low fat (LF) or high fat (HF) diet.  Mice were fed experimental diet from weaning 
(at 3 weeks of age) to the end of the study (24 weeks of age). Data are mean body 
weight of each group ± SEM, n=12/group. 2-way repeated measures ANOVA 
showed a significant effect of diet in both sexes (p<0.001) and a significant effect 
of genotype in HF-fed female mice from week 19 onward (*P<0.05, ** P<0.01, 
***P<0.001) 
Keys Male non-tg LF(■), male tg LF(■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF(■), female non-tg HF (■) and female tg 
HF(■). 
 





               The transfection studies demonstrated that the cloned rat GR cDNA 
fragment is functional. It was not possible to confirm that the aP2 enhancer/promoter 
fragment was active due to a lack of a suitable cell line. However, similar aP2 
enhancer/promoter constructs have been reliably used to express transgenes in 
adipose tissue of mice (Moitra, Mason et al. 1998; Shimomura, Hammer et al. 1998; 
Masuzaki, Paterson et al. 2001; Kershaw, Morton et al. 2005) Preliminary 
examination of F1 tg mice by real-time PCR showed adipose-specific expression of 
rat GR mRNA and also showed a significant increase in adipose tissue weight in 
female D-FSG mice at 4-5 months of age. Due to time and animal constraints, the 
initial phenotyping of D- and B-FSG lines was carried out on the second (F2) 
generation. Between the two transgenic lines, D-FSG was selected for a 24 week 
high fat diet study, but no difference in body weight gain, adipose tissue weights, 
blood pressure, plasma lipid or liver triglyceride levels was found on either LF or HF 
diet in either sex. However, in 1 year old F1 chow-fed female mice, the difference in 
adipose tissues was maintained, at least in gonadal fat. The reason for the loss of 
adipose phenotype at F2 is unclear. Competitive (semi-quantitative) PCR using 
various adipose tissue depots from tg mice from different generations showed rat GR 
mRNA was expressed in both transgenic lines with very low levels of transgene 
expression in adipose tissue of B-FSG mice and clearly detectable levels in D-FSG 
mice.  However, the PCR assay also showed great variability between mice within 
each line and between adipose depots within individual mice, with no expression in 
some adipose tissue of some tg mice.  In addition, little or no transgene expression 
was detected by RPA in adipose depots of any generation, nor did total GR mRNA 
(endogenous mouse plus transgenic rat) differ between tg and non-tg mice. It is also 
possible that mouse GR mRNA was down–regulated to compensate for transgene-
derived GR mRNA. However, no evidence was obtained to support this. 
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Figure 4.27 Following HF diet, female GR-5 mice show reduced adipose tissue 
mass compared to non-tg littermates 
Adipose tissue and organ weights of GR-5 (F2 generation) mice fed LF diet or HF 
diet. (A) male and (B) female mice. Data are expressed as % of body weight of 
each group and are mean ± SEM, n=12/group. 2-way ANOVA and shown no 
significant difference in the LF diet and significant in HF diet when compare to 
non-tg control (*P<0.05) 
Tissues and organs are subcutaneous (Sc), gonadal (Gon), Mesenteric (Mes) 
adipose and liver (liv). 
Key: Male non-tg LF(■), male tg LF(■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF(■), female non-tg HF (■) and female tg 
HF(■).





Figure 4.28 Reduction in body weight and adipose accumulation in female GR-5 
transgenic mouse upon HF diet 
Appearance of HF fed female GR-5 (F2 generation) mice with non-tg littermate 
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Figure 4.29 Unaltered glucose tolerance in GR-5 transgenic mice 
Glucose tolerance tests (GTT) in 26-27 week old GR-5 (F2 generation) non-tg 
(straight line) and tg (dashed lines) mice fed LF (square symbols) or HF 
(triangular symbols) diets; (A) male and (B) female. For GTT, mice were fasted 
for 6h; blood was 0 and 15, 30, 60 and 120 min after intraperitoneal injection of 
glucose (2mg/g body weight) at time 0. Data are expressed as mean plasma 
glucose level ± SEM. N=6/group. Data were analysed by repeated measures 2 
way-ANOVA.  
Key: Male non-tg LF(■), male tg LF(■), male non-tg HF (■), male tg HF (■), 
female non-tg LF (■), female tg LF(■), female non-tg HF (■) and female tg 
HF(■).  
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Unfortunately, these assays could not be performed on F1 female D-FSG tg 
mice due to insufficient tissues. It is possible that transgene expression decreased 
between F1 and subsequent generations, although this could not be confirmed. With 
hindsight, greater quantitative analysis should have been performed on the F1 and F2 
generations before carrying out the HF diet study, to establish whether total adipose 
tissue GR mRNA was elevated in tg mice. 
In parallel, aP2-anti-sense GR mice (GR-5 line) were produced by Dr. Elaine 
Marshall and preliminary characterization was carried out on the F1 generation of 
these mice. Similar to the aP2-GR tg mice, adipose tissue weights differed only in 
female mice, with lower adipose tissue weight in the tg mice compared to the non-tg. 
As with the D-FSG mice line, a 24 week high fat diet study was carried on the F2 
GR-5 mice. From week 19 of the study onward, HF-fed tg female mice showed a 
significant reduction in body weight gain, but such a reduction was not observed in 
the LF-fed female group; only a trend to lower body weight was observed. This 
could be due to the low fat content of the LF diet (compared to the chow diet fed to 
F1 mice) which might not produce a difference in body weight as observed in the 
chow-fed mice group. To investigate whether the reduction in body weight of the 
HF-fed tg female mice was due to reduced food intake, this should be measured. 
Unfortunately in this experiment, such measurement was not possible as the majority 
of the mice shredded the food and scattered it within the cages. A future experiment 
should either use metabolic cages or a computerised system to measure daily food 
and water consumption. The reduction in body weight of the HF-fed tg mice 
compared to controls could also be explained by increased metabolic rate. 
Measurement of both core body temperature and oxygen consumption would be 
needed to test this. 
To establish whether GR protein expression was reduced within adipose 
tissues of tg mice, western blotting was carried out. To date, the results have been 
inconclusive as variable measurements have been obtained from the same tissue 
samples, which could be due to protein escape during loading, incomplete protein 
transfer or incorrect extraction method. Further investigation is required to establish 
whether there is a reduction in GR levels in adipose tissues of GR-5 mice.  
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To investigate whether the HPA axis is normal in tg mice, adrenal weight of 
the mice as well as plasma corticosterone levels in both morning and evening should 
be measured. In addition, measurement of levels of plasma corticosterone during HF 
diet should be investigated. Measurement of glucocorticoids and their metabolites in 
urine collected from the metabolic cages would give an insight into the clearance 
rate of plasma corticosterone in these mice.   
Quantitative (real-time) PCR should be carried out on adipose tissues 
obtained from the dietary study to examine levels of mRNA encoding leptin which 
plays an important role in appetite regulation; adiponectin, which is involved in 
regulation of fatty acid metabolism, uncoupling protein 1 (UCP1) which is involved 
in thermal regulation as well as other metabolically important genes.  
As glucocorticoids affect lipolysis within adipose tissue, fasting free fatty 
acid levels as well as liver triglyceride levels should also be measured to look at the 
effect of adipose GR on free fatty acid trafficking. In addition, Sc as well as Mes 
adipose tissue could be stained with oil red O to investigate any change in fat cell 
size in tg mice fed high fat diet. 
In the HF diet study, male tg mice did not display any difference in body 
weight gain throughout the study under both diet conditions. However, both Sc and 
Gon fat depots were found to be heavier in the HF fed-tg mice compared to controls. 
The mechanism causing this remains unclear, especially given the opposite effect to 
that seen in females. However, such difference could be due to the sex-specific 
difference in glucocorticoid biology, with female having larger adrenal glands and 
exhibiting higher level of basal corticosterone (Le Mevel, Abitbol et al. 1979). 
Similar sex-specific phenotypes have been observed in GR+/- mice (Michailidou Z. 
(2008) PhD thesis, University of Edinburgh). They exhibit a hyperactive HPA axis, 
with enlarge adrenal glands and elevated evening plasma corticosterone levels in 
both sexes. However, only male mice exhibit an elevated corticosterone response 
after acute stress (Michailidou Z. (2008) PhD thesis, University of Edinburgh). 
Alternatively, gonadal steroids also play an important role in energy balance and 
potently influence body composition (reviewed in Lovejoy and Sainsbury 2009). The 
phenotype difference observed here could due to an interaction of GR with sex-
specific adipose functions. 
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In the meantime, more detailed characterization of the GR-5 mice transgene 
expression pattern is also needed. Although initial real-time data from B-FSG and D-
FSG had shown no rat GR mRNA expression were found in kidney and liver. 
However recent studies have shown aP2 gene expression in brain, lung and 
macrophages (Liu, Quinet et al. 2007). To test whether the phenotype observed is the 
consequence of transgene expression in adipose tissues, in situ hybridization could 
be carried out on brain tissue to look for transgene expression. To ensure expression 
observed in adipose tissues was solely from the adipocyte, adipose tissues from 
transgenic mice could be collagenase digested and separated into adipocyte and 
stromal vascular layers, and transgene expression measured in each fraction using 
real-time PCR. In addition, to test that the phenotype was not due to transgene 
expression in macrophages or other immune cells, a bone marrow transplant 
experiment could be carried out. To deplete bone marrow cells, GR-5 and WT 
(C57BL/6 mice) recipient mice would be lethally irradiated, then bone marrow cells 
reconstituted, form either GR-5 or WT mice. Establishing whether the obesity-
resistant phenotype followed the host genotype or the recipient genotype would 
determine whether transgene expression in the adipocyte or the macrophage is 
responsible for the observed phenotype. Nevertheless, the preliminary data reported 
here suggests that GR density in adipocyte may be an important determinant of 
adipose tissue accumulation in mice. 
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5 Discussion 
Substantial evidence links disturbances of fatty acid metabolism and 
glucocorticoid (GC) action in obesity. Tissue GC actions are determined by GR 
density and ligand availability, the latter depending upon circulating plasma 
corticosterone levels and activity of an intracellular enzyme-11β-HSD1. In this 
thesis I have investigated the interaction of environmental and genetic manipulations 
upon adipose GC action and its impact upon obesity.  
 Data from the dietary fatty acid-enrichment studies showed unaltered 
adipose and liver GR mRNA expression levels among all diet groups. However, 
differential effects on adipose 11β-HSD1 mRNA levels were observed between the 
stearate fed-group and all the other groups, especially the oleic acid group. This was 
more apparent in study 2, where the diets were fed ad libitium and the oleic acid fed 
group showed the same pattern of down-regulation of adipose 11β-HSD1 expression 
along with a marked increase in body weight as observed in the 58% mixed fat diet 
and also the 45% mixed fat diet, although to a lesser extent. Thus, unsaturated fat 
(when predominates in the mixed fat diet), down-regulated adipose 11β-HSD1. 
However, the reverse pattern was seen in the stearate fed-group whether pair-fed or 
fed ad libitium with increased adipose 11β-HSD1 mRNA levels and activity, 
accompanied by elevated plasma corticosterone levels and reduced fasting plasma 
insulin levels. This suggested that adipose 11β-HSD1 mRNA levels might be highly 
regulated by GC, since the substrate for 11β-HSD1 (11-dehydro-corticosterone) is 
elevated upon activation of HPA axis (e.g. following stress) (Harris, Kotelevtsev et 
al. 2001), potentially producing a “feed-forward” regulation of GC action in adipose 
tissue. This hypothesis is further validated in POMC null mice (which lack 
endogenous GC), where corticosterone replacement resulted in increased adipose 
11β-HSD1 mRNA levels but unaltered hepatic 11β-HSD1 mRNA levels 
(Michailidou, Coll et al. 2007). This is also apparent in C57BL/6 wild type mice in 
which high physiological GC levels (but not supraphysiological) caused an increase 
in adipose 11β-HSD1 mRNA (Michailidou, Coll et al. 2007). Similarly, GC 
administration in rat increased adipose 11β-HSD1 mRNA and activity 
(Balachandran, Guan et al. 2008). However, such an increase was not observed in 
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vitro in GC-treated differentiated 3T3-L1 adipocytes, which model many aspects of 
adipocyte biology (Balachandran, Guan et al. 2008). Furthermore, these studies were 
conducted in a relativly short period of time (1 week); in contrast mice fed high fat 
diet for a longer period present a chronically activated HPA axis yet still show a 
down regulation of 11β-HSD1 (Morton, Ramage et al. 2004), though this is not seen 
in rat (Drake, Livingstone et al. 2005). Thus, other factors than simply plasma GC 
levels or 11β-HSD1 substrate levels are likely to be involved in the up-regulation of 
adipose 11β-HSD1 seen in the stearate-fed mice and regulation of adipose GC action 
may be complex.  
An unexpected observation from the two control diet groups in Study 2 was 
an elevation in mesenteric fat and liver 11β-HSD1 activity levels but unaltered 11β-
HSD1 mRNA levels between the groups. This suggests that the control sucrose diet 
might be triggering a different pathway to the control cornstarch diet, which acts 
post-transcriptionally to modulate 11β-HSD1 activity. 11β-HSD1 reductase activity 
depends on the availability of the nicotinamide co-factor NADPH, which is 
produced within the endoplasmic reticulum lumen by the enzyme hexose-6-
phosphate dehydrogenase (H6PDH), physically associated with 11β-HSD1 
(Atanasov, Nashev et al. 2008). Recent studies have shown that mutations in H6PDH 
cause cortisone reductase deficiency (CRD), in which activation of cortisone to 
cortisol (11β-reductase activity) does not occur (Draper, Walker et al. 2003; Lavery, 
Walker et al. 2008). Initial studies had suggested that alterations in the 11β-HSD1 
gene could contribute to CRD (Draper, Walker et al. 2003). However, recent re-
analysis showed that deficiency in 11β-reductase activity in CRD is entirely due to 
H6PDH mutations without alteration in 11β-HSD1 (Lavery, Walker et al. 2008). 
However, H6PDH expression and activity levels were not examined in the studies 
reported in this thesis, thus it is not known whether the control diet differentially 
regulated H6PDH. This should be examined in the future. Interestingly, a study in 
rats has shown an effect of sucrose on H6PDH expression and consequently on GC 
metabolism (London, Lala et al. 2007). Rats with access to the drinking sucrose 
solution showed increased 11β-HSD1 and H6PDH mRNA levels in mesenteric fat 
and a reduction in liver 11β-HSD1 mRNA levels, the latter accompanied by an 
increase in H6PDH mRNA levels (London, Lala et al. 2007). This suggests dietary 
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sugar (e.g. sucrose or possibly fructose or glucose) influences 11β-HSD1 mRNA 
levels. In the study reported here, the control diet enriched in sucrose did not alter 
11β-HSD1 mRNA levels in liver and mesenteric fat compared to control diet 
enriched in cornstarch but it did increase mesenteric and subcutaneous fat 11β-HSD1 
enzyme activity and the reverse in liver. Because the activity assays carried out here 
were homogenate assays, H6PDH is assumed not to play an important role in the 
assay (NADP is added as co-substrate with corticosterone in 11β-dehydrogenase 
activity assays carried out with homogenates). It is also possible that 11β-HSD1 
interaction with H6PDH might alter post-translational modification of 11β-HSD1, 
(e.g. glycosylation) which might regulate activity.  
The results presented in this thesis suggest that GC receptor density may be 
an important determinant of adipose tissue accumulation in obesity, although 
possibly only in females. Although the experiments designed to increase GR density 
in adipose initially produced promising data, the subsequent high fat diet experiment 
failed to show any effect. The follow-up investigation revealed variation in adipose 
tissue GR density within a single tg mouse and between mice from different 
generations. However, female mice with decreased adipose GR density appeared to 
be protected from obesity. Further work is needed to establish the mechanisms but 
the finding is of great interest.  
Mice with globally reduced GR gene density (GR+/-) showed an entirely 
normal response to high fat diet, in terms of weight gain, adiposity, lean mass and 
insulin/glucose homeostasis (Michailidou, Carter et al. 2008). They also showed a 
compensatory increase in HPA axis activity with increased plasma corticosterone 
levels (Michailidou, Carter et al. 2008). In contrast, mice with globally reduced GR 
density, due to expression of an antisense-rat GR transgene under the control of a 
human neurofilament gene promoter (a very similar anti-sense GR construct to the 
one used in this thesis) were obese and also had elevated circulating corticosterone 
levels; these mice therefore had disturbances in both HPA axis regulation and 
metabolism (Pepin, Pothier et al. 1992; Richard, Chapdelaine et al. 1993). The 
differences between the anti-sense GR mice and the GR+/- mice may be due to a 
variable expression of the anti-sense transgene, particularly in the brain, where the 
promoter was designed to target. Although GR-5 mice carry a very similar anti-sense 
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GR transgene, expression was designed to be restricted to adipose tissue. These mice 
show an opposite, lean phenotype, suggesting that the effect on HPA axis and ligand 
availability in the global anti-sense GR mice may over-ride the local effects of 
reduced GR density in adipose tissue. It is also possible that GR density in adipose 
tissue was little affected by the transgene in the global anti-sense transgenic mice. In 
addition, the data reported here suggest that adipose GR density is only limiting in 
the accumulation of adipose tissue in female mice on a high fat diet. It is also 
important to note that the female mice tested here were young, as they were weaned 
onto the high fat diet. Unfortunately, due to time constraints, it was not possible to 
measure 11β-HSD1 mRNA levels in adipose tissue of GR-5 mice and it will be 
important to investigate this in the future. However, evidence from male GR+/- mice 
has shown unaltered levels of 11β-HSD1 mRNA in all adipose tissues (Michailidou, 
Carter et al. 2008). Reduced GC levels in adipose tissue, through transgenic 
expression of 11β-HSD2 in adipose tissue (aP2-11β-HSD2 mice), produced a 
phenotype with similarities to GR-5 mice in resistance to weight gain, reduced fat 
accumulation and increased energy expenditure (Kershaw, Morton et al. 2005). 
However, energy expenditure of GR-5 has not been investigated in the experiments 
reported here and will be needed in future studies. Taking into account that only 
male aP2-11β-HSD2 mice were reported (Kershaw, Morton et al. 2005). However, 
both sexes of aP2-11β-HSD1 transgenic mice are obese and hyperphagic, with 
elevated adipose corticosterone levels but normal plasma concentrations (Masuzaki, 
Paterson et al. 2001). In our study, only female mice exhibited the reduction in 
weight, suggesting that differential regulation of adipose GC action in males and 
females, with GC levels more important in males and GR density more important in 
females, where circulating GC levels are higher (Kitay 1961). Taken together, the 
findings suggest that the effect of GR density on adipose GC action can be over-
ridden by increased 11β-HSD1 activity levels which affect adiposity in both sexes.   
Obviously, there are limitations to the experiments reported here. The dietary 
fat manipulation experiments were only carried out in males yet the effect of altered 
GR density was only seen in females. The dietary studies (Study 1 and 2) were 
carried out on males to avoid complications due to the effects of the oestrus cycle in 
females. Sex steroids, especially oestrogen, may play an important role in adipose 
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tissue accumulation. It is well know that prior to menopause, women carry more fat 
in peripheral depots (gynoid distribution) whereas men carry more fat viscerally 
(android distribution). However, after menopause women accumulate more fat in the 
abdominal and visceral regions, becoming more android-like in the fat distribution 
(Shi, Seeley et al. 2009). The effect of GR density in the studies reported here related 
to relatively young and reproductively viable females, which may mirror the 
situation in humans prior to menopause and suggest that oestrogen may be an 
important factor in the phenotype. Sex hormones have a considerable influence on 
adipose accumulation and the development of metabolic syndrome. Various mouse 
models have shown that sex steroids have significant influences on fat distribution. 
Visceral obesity and insulin resistance were observed in estrogen receptor-α 
knockout mice (αERKO) and in ArKO mice deficient in aromatase, the enzyme that 
produces estradiol from its precursor testosterone (Heine, Taylor et al. 2000; Jones, 
Thorburn et al. 2000). On the other hand, mice that lack the nuclear receptor co-
repressor, Receptor Interacting Protein 140 (RIP140) in which estrogen action is 
increased, shown a lean phenotype and resistance to diet-induced obesity 
(Leonardsson, Steel et al. 2004). It is possible that GC and oestrogen pathways 
interact in a sex-specific manner to regulate obesity. At one level, the effect of sex 
upon the HPA axis is well known, with a higher level of HPA activity in females. It 
is also possible that these pathways interact locally, within adipose tissue to regulate 
adipocyte function and adipose tissue metabolism. This will be an important area to 
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Appendix A: Address of suppliers  
 
Amersham Pharmacia Biotech UK Ltd 
Amersham Place, Little Chalfont, Bucks, UK, HP7 9NA 
 
Anachem Ltd 
Anachem House, 20 Charles Street, Luton Bedfordshire, UK, LU2 0EB  
 
Applied Biosystems 
7 Kingsland Grange, Woolston, Warrington, Cheshire, UK WA1 4SR 
 
BDH Merck Ltd 
VWR International LTD, Merck House, Poole, Dorset, UK, BH15 1TD 
 
Becton, Dickinson and company 
The Danby Building, Edmund Halley Road, Oxford Science Park, Oxford, 
Oxfordshire, UK, OX4 4DQ 
 
Bio-Rad Laboratories Ltd 
Bio-Rad House, Maxted Road, Hemel Hempstead, Hertfordshire, UK, HP2 7DX 
 
Cambrex Corporation 
One Meadowlands Plaza, East Rutherford, NJ 07073 USA 
 
Cambridge BioScience Ltd 
24-25 Signet Court, Newmarket Road, Cambridge, UK, CB5 8LA 
 
Fisher Scientific UK Ltd 
Bishop Meadow Road, Loughborough,  Leicestershire, UK, LE11 5RG 
 
Hayman Ltd 
Eastways Park, Witham, Essex, UK, CM8 3YE 
 
Invitrogen Life Technologies 
Ichinnan Bussiness Park, 3 Fountain drive, Paisley, UK, PA4 9RF 
 
Promega Corporation 
Delta House, Southampton Science Park, Southampton, Hampshire, UK, SO16 7NS 
 
PerkinElmer 
Chalfont Road, Seer Green, Beaconsfield, Bucks, UK, HP9 2FX 
 
Qiagen Ltd 
Qiagen house, Fleming way, Crawley, West Sussex, UK, RH10 9NQ 
 
Research Diets, Inc. 
20 Jules Lane, New Brunswick, NJ, USA, 08901 
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Roche Diagnostic Ltd 
Charles Avenue, Burgess Hill, West Sussex, UK RH15 9RY 
 
Sigma-Aldrich Company Ltd  
The Old Brickyard, New Road, Gillingham, Dorset, UK, SP8 4XT 
 
Santa Cruz Biotechnology, Inc. 
2145 Delaware Avenue, Santa Cruz, California, 95060, U.S.A. 
 
Thermo Fisher Scientific Inc. 
81 Wyman Street, Waltham, MA, USA 02454 
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